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Migraine is one of the most prevalent contributors to the global burden of mental 
and neurological disorders. It is a complex episodic condition that presents as intense 
recurrent unilateral headaches lasting hours to days that can be accompanied by nausea, 
photophobia, phonophobia and other neurological symptoms. The causes of migraine 
appear multifactorial and are not fully understood. However, activation of the 
trigeminovascular system and sphenopalatine parasympathetic neurons and the resulting 
vasodilation of meningeal arteries have been associated with the development of 
migraine pain. Recently, the neurotransmitter and neurotrophic peptide pituitary 
adenylate cyclase activating polypeptide (PACAP) has been implicated in this migraine 
headache pathway. The effects of PACAP parallel those of other migraine inducing 
agents and notably PACAP induces vasodilation of the MMA concurrent with the genesis 
of migraine headache when administered to human subjects. The mechanisms by which 
PACAP induces dilation are presently unclear. The objective of this present work was to 
elucidate the signaling pathways linking PACAP to MMA dilation. To achieve this 
objective, we developed an ex vivo approach to study isolated MMA at physiologically 
relevant intravascular pressure. Using this preparation we found that PACAP dilates 
MMA at picomolar concentrations via PAC1 receptors. Further, in MMA, PACAP-
induced dilation is mediated exclusively though activation of KATP channels. While 
investigating the mechanisms of PACAP-induced dilation of MMA we discovered that 
basal KATP channel activity influences MMA diameter.  
Inhibition of KATP channels with glibenclamide or PNU37883 at physiological 
intravascular pressure resulted in a vasoconstriction of ≈ 20 %. Also consistent with basal 
KATP activity, glibenclamide induced a membrane potential depolarization of ≈ 14 mV. 
Further, in MMA loaded with the ratiometric Ca2+ indicator, Fura-2-AM, glibenclamide-
induced MMA constriction was correlated with a simultaneous increase in the ratio of 
340 nm/380 nm excited fura-2 fluorescence, consistent with an increase in intracellular 
Ca2+.  
Vascular smooth muscle KATP channels can be phosphorylated and activated by 
PKA, resulting in membrane potential hyperpolarization. KT5720, a PKA inhibitor, 
induced a constriction in MMA similar to that of glibenclamide (≈ 25 %). Additional 
treatment with glibenclamide did not induce further constriction suggesting that PKA 
activity may underlie tonic KATP channel activation. Together these results suggest that 
tonic PKA activity underlies basal KATP channel activity and together play a key role in 
regulation of MMA diameter. 
In summary, results presented in this dissertation suggest that picomolar PACAP-
induced dilation of MMA is via activation of the PAC1-Hop1 receptor splice variant and 
KATP channel activation. Furthermore, KATP channels are also involved in tonic regulation 
of MMA diameter due to basal PKA activity. These unique features of the MMA provide 
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Migraine is defined as a debilitating neurological disorder characterized by 
episodes of severe, throbbing headache, which are frequently unilateral in nature. The 
duration of migraine headache ranges from 4 to 72 hours and is generally accompanied 
by one or all of the following symptoms: nausea, photophobia, phonophobia and 
allodynia (Goadsby et al., 2002).  The causes of migraine are not clear. Two competing 
theories regarding the pathophysiology of migraine are the theory of central sensitization 
and the vascular theory of migraine. The theory of central sensitization postulates that 
abnormal neuronal excitability of the second order brain stem neurons of the trigeminal 
nucleus caudalis (TNC) results from a noxious stimulus causing hyperexcitibility of the 
peripheral trigeminal nerves. This central sensitization is prolonged and can last up to 10 
hours corresponding to the duration of migraine headaches (Burstein et al., 1998, Dodick 
and Silberstein, 2006). Thus, as a result of central sensitization, the migraine patient will 
experience exaggerated and intensified pain in response to a stimulus that ordinarily 
would cause mild pain.  
In the 1940’s Dr. Harold Wolff and his colleagues observed that mechanical 
distention and vasodilation of the cranial blood vessels and more specifically the middle 
meningeal artery (MMA) results in headache pain. They further postulated that this 
headache pain is similar to migraine headache. These experimental observations gave 
birth to the vascular theory of migraine headache (Ray BS, 1940). At the time, it was 
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already recognized that the dura mater containing the MMA is heavily innervated by 
sensory neurons (Schueler et al., 2013). Over time, the vascular theory of migraine has 
undergone several modifications, yet the vasodilation of MMA is still considered a key 
player in migraine headache. However the stimuli for the vasodilation has not been 
clearly established (Goadsby et al., 1990).  In 1979, Moskowitz et al. proposed that 
neurogenic inflammation contributes to the pathophysiology of migraine. According to 
this theory, activation of the trigeminal sensory ganglion and/or the sphenopalatine 
ganglion nerve endings causes an increase in release of vasoactive neuropeptides such as 
calcitonin gene related peptide (CGRP) and Substance P (SP) from the nociceptive Aδ 
and C fibers respectively on to the cranial vessels resulting in vasodilation (Moskowitz et 
al., 1979). The resultant distention of the blood vessels is further sensed by the afferent 
sensory nerves innervating the arterial wall and is communicated to the brain where the 
signal is subsequently perceived as pain (Ray BS, 1940, Goadsby et al., 2002, Asghar et 
al., 2010, Asghar et al., 2011, Amin et al., 2012, Amin et al., 2014)  (Figure 1). 
Until recently “the vascular theory of migraine” had lost momentum. However, in 
2011 Asghar et al. provided functional and visual evidence using magnetic resonance 
angiography (MRA) for the vascular involvement in migraine headache. In this clinical 
study, intravenous (IV) injection of CGRP (1.5 µg/min for 20 minutes) was given to 
migraine patients to induce and mimic migraine headache. CGRP has been previously 
reported to induce migraine–like symptoms when given to both healthy subjects and 
migraine patients (Asghar et al., 2011). Asghar et al. observed that injection of CGRP 
induced migraine like symptoms including headache in the subjects. Furthermore, 
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patients with unilateral migraine or headache had concomitant dilation of the MMA on 
the pain side but not on the non-headache side. Conversely, middle cerebral artery 
(MCA) dilated on both the headache and non-headache sides. Additionally, when the 
patients were acutely given the anti-migraine drug sumatriptan (a 5-HT-1B/D  receptor 
agonist), the attenuation of the headache coincided with the constriction of MMA on the 
headache side. However, MCA diameter remained unchanged. The evidence presented in 
this study highlights two key points; 1) there is a vascular component to migraine 
headache, and 2) MMA but not MCA dilation may be responsible for the onset of 
migraine headache (Asghar et al., 2010, Asghar et al., 2011). Moreover, in follow-up 
studies, Amin et al. presented a similar out come in both healthy volunteers and 
migraineurs with another potent vasodilator, pituitary adenylate cyclase activating 
polypeptide (PACAP) (Amin et al., 2012, Amin et al., 2014). In addition, recent studies 
also suggest that the levels of PACAP and CGRP in plasma and cerebrospinal fluid 
(CSF) from migraineurs are significantly higher during migraine headaches (Cernuda-
Morollon et al., 2013, Tuka et al., 2013, Bukovics et al., 2014). These studies brought the 
spotlight back on to the physiological and pathophysiological role of MMA and the effect 
of the neuropeptide PACAP on MMA during migraine headache (Schytz et al., 2009, 
Asghar et al., 2010, Schytz et al., 2010a, Schytz et al., 2010b).  
The following literature review will provide an overview of the regulation of 
MMA by PACAP. Section one will discuss the vasodilatory effects of PACAP on blood 
vessels followed by a comparison of the mechanisms of vasodilation in MMA vs. the 
cerebral vasculature. Additionally, during our attempts to decipher mechanism of 
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PACAP-induced dilation of MMA, we discovered that ATP-sensitive potassium (KATP) 
channels are tonically active in the MMA. Thus, section two of this review will focus on 
the role of KATP channels with emphasis on vascular smooth muscle. 
1.2 Section 1 
1.21 Vascular components of migraine headache: meninges and the MMA 
Meninges consist of three membranous layers of connective tissue, which work 
together to form a protective barrier around the brain and spinal cord. The three layers are 
identified as dura mater, arachnoid mater and pia mater. Dura mater is the outer most 
layer apposed to the calvaria. Embryonically, dural tissue is derived from the mesoderm. 
In constrast, the pia and arachnoid mater are derived from the ectoderm (Gil and Ratto, 
1973). Dura mater is described as a pain sensitive tissue innervated by sensory nerves 
originating from the trigeminal ganglion. Structurally, dura mater consists mainly of 
connective tissue, but also has a population of dural mast cells. Mast cells are part of the 
immune system, containing granules rich in histamine and other inflammatory mediators 
that have been shown to play a key role in the inflammatory process (Dimitriadou et al., 
1997, Baun et al., 2012). The main artery supplying blood to the dura mater is the MMA 
(Yoshida et al., 1966, Chmielewski et al., 2013). The MMA branches from the maxillary 
artery,  passes through foramen spinosum to enter the middle cranial fossa and course 
with in the dura mater (Figure 2) (Chmielewski et al., 2013). 
The MMA displays autoregulation, an intrinsic property of resistance arteries 
occurring in response to increasing intravascular pressure that is modulated by metabolic 
and endothelium-dependent mechanisms (Michalicek et al., 1996, Li et al., 2014). 
Increases in intraluminal pressure induce membrane potential depolarization, activation 
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of L- type voltage gated calcium channels (L-VDCC), vascular smooth muscle 
contraction and vasoconstriction (Knot and Nelson, 1998). This mechanism allows 
resistance arteries to maintain a constant level of blood flow during fluctuations in 
systemic blood pressure. Interestingly, the dura mater does not display high metabolic 
demand, thus the physiological reason for MMA to display autoregulation is not clear. 
1.22 Neural inputs to MMA  
The German anatomist, Arnold F. Der Kopfteil first described the innervation of 
the dura mater with trigeminal sensory nerve fibers also known as the V cranial nerve in 
1831. This observation later played a pivotal role in describing the generation of 
headache. Several studies have linked trigeminal sensory nerve activation in the dura 
mater to the sensation of pain (Yoshida et al., 1966, Schueler et al., 2013). Since then, a 
number of studies have demonstrated innervation of the meningeal blood vessels in the 
dura mater originating from different sources including sympathetic fibers from the 
superior cervical ganglion, trigeminal fibers from the trigeminal ganglion and 
parasympathetic nerve fibers from the sphenopalatine and otic ganglia (Edvinsson et al., 
2001, Goadsby, 2013, Schueler et al., 2013).  Peptides released from these perivascular 
nerves can regulate the diameter of the meningeal vascular bed. For example, the 
sympathetic fibers release vasoconstriction-inducing neuropeptide Y (NPY) and 
norepinephrine (Uddman et al., 1993a, Goadsby, 2013, Tajti et al., 2015), trigeminal 
fibers release vasodilatory neuropeptides such as PACAP, vasoactive intestinal 
polypeptide (VIP), Substance P and CGRP (Uddman et al., 1993a, Edvinsson et al., 
2001), and the parasympathetic fibers originating from the sphenopalatine ganglion 
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release PACAP and CGRP (Csati et al., 2012a, Csati et al., 2012b). It is worth 
mentioning that the number of neurons demonstrating PACAP immunoreactivity differs 
between trigeminal and parasympathetic ganglia, with approximately 10% in the 
trigeminal population and 6-5% in the sphenopalatine and otic ganglia  (Csati et al., 
2012a, Csati et al., 2012b).  
Interestingly, there is co-localization of PACAP and CGRP in some of the nerves 
innervating the MMA although the identity of these nerves is not clear (Edvinsson et al.). 
Both peptides can be simultaneously released upon neuronal stimulation to cause dilation 
of the MMA (Edvinsson et al., 2001). The requirement for two different peptides 
(PACAP and CGRP) with overlapping functions within the same nerve fiber is unknown.  
1.23 PACAP and its receptors 
 
PACAP is classified as both a neuropeptide and a hormone. It is a member of the 
structurally related peptide hormone family that includes glucagon, secretin, vasoactive 
intestinal peptide (VIP), gastric inhibitory peptide and growth hormone-releasing 
hormone. PACAP was first isolated from ovine hypothalamus extract in 1989 and was 
named for its role in stimulating adenylyl cyclase (AC) and in turn increasing cyclic 
adenosine monophosphate (cAMP) levels (Miyata et al., 1989). PACAP has been 
evolutionarily conserved for over 700 million years, indicating that PACAP and its 
pleiotropic functions are important for survival. PACAP knockout mice display altered 
anxiety levels and depression behavior (Gaszner et al., 2012). PACAP is synthesized as a 
precursor peptide which is then cleaved by pro-hormone convertases including PC1, PC2, 
PC4 and furin (Seidah et al., 1994, Seidah and Chretien, 1999) resulting in either 
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PACAP38 (38 amino acids) or PACAP27 (27 amino acids), the two endogenously active 
forms of PACAP (Miyata et al., 1990). While both isoforms have similar binding 
affinities for PACAP receptors, their potencies for second messenger activation appear 
dissimilar. PACAP 38 has been demonstrated to stimulate phospholipase C (PLC) with 
higher potency compared to PACAP 27 (15 nM vs. 1 µM respectively) (Journot et al., 
1995). Furthermore, Braas et al. have demonstrated that PACAP 38 is 10 times more 
potent than PACAP 27 in stimulating cAMP production in superior cervical ganglion 
(SCG) neurons. Additionally, PACAP 38 is the more predominant isoform in brain tissue 
and nervous system (Sherwood et al., 2000). 
PACAP 27 or 38 can bind to three distinct receptors, PAC1, VPAC1 and VPAC2, 
which have been divided into 2 classes based on their relative PACAP binding affinities 
(Sherwood et al., 2000). PAC1 receptors have been traditionally identified as the type 1 
PACAP selective receptor with a binding affinity to PACAP 1000 fold higher compared 
to its binding affinity for the structurally similar peptide vasoactive intestinal polypeptide 
(VIP) with a Kd value of 0.5 nM for PACAP vs. 500 nM for VIP. In contrast, the type 2 
VIP /PACAP receptors, VPAC1 and VPAC2, have equal binding affinities for PACAP 
and VIP with a Kd value of 1 nM (Sherwood et al., 2000, Vaudry et al., 2009). 
The PACAP selective PAC1 receptor has several splice variants due to alternative 
splicing of the transcript from a single gene. The PAC1 receptor isoforms can have no 
additional inserts, a hip cassette, a hop cassette or both hip and hop cassettes incorporated 
in the third intracellular loop. Accordingly, the PAC1-R splice variants are characterized 
by the absence null or the presence of either one or two of the 28 amino acid cassettes 
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(hip or hop1) or the 27 amino acid cassette Hop2. Six splice variants have been identified 
for PAC1 receptors: PAC1-R-null, PAC1-R-hop1, PAC1-R-hop2, PAC1-R-hiphop1, 
PAC1-R-hiphop2 and PAC1-R-hip (Journot et al., 1995). All splice variants of PAC1 
receptors with the exception of PAC1-R-hip can couple to and activate Gs or Gq/11 with 
equal potencies but with varying degrees of efficacy. PAC1-R-hip can only activate AC 
(Journot et al., 1995, Sherwood et al., 2000).  Thus, alternative splicing of the PAC1 
receptor mRNA confers differences in G protein coupling and downstream signaling 
pathways.  
The type 2 receptors VPAC1 and VPAC2 are also coupled with Gs protein and 
upon activation increase cAMP. Both PACAP and VIP can activate VPAC1 and VPAC2 
with equal potency (Pisegna and Wank, 1993, Journot et al., 1995, Shioda et al., 1996, 
McCulloch et al., 2001, Dickson and Finlayson, 2009). The distribution of the type 1 and 
type 2 PACAP receptors varies between tissues with all three receptors PAC1, VPAC1 
and VPAC2 reported in arterial smooth muscle (Warren et al., 1991, Chan et al., 2011, 
Syed et al., 2012).  
1.24 PACAP and nonvascular functions 
 PACAP is a pleiotropic neuropeptide involved in multiple systems throughout the 
body. PACAP has been reported to play a role in cell cycle and development. For 
example, PACAP is reported to stimulate proliferation of chromaffin cells and primordial 
germ cells (Tischler et al., 1995). Not only does PACAP stimulate proliferation but it also 
regulates differentiation. PACAP activation of PAC1-R is known to stimulate neurite 
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growth. Additionally, PACAP also been described to initiate and inhibit apoptosis 
(Sherwood et al., 2000). 
 One of the major roles of PACAP is as a regulator of the nervous system. For 
example PACAP levels during circadian rhythms decrease during daytime and increase 
during nighttime in the retinal ganglion cells that send axons to the suprachiasmatic 
nucleus, a region responsible for generating circadian rhythms (Fukuhara et al., 1997). 
More recently, PACAP has been demonstrated to play a key role in anxiety behavior. 
Hammack et al. have reported increased levels of PACAP and PAC1 receptor transcripts 
after chronic stress in the bed nucleus of the stria terminalis (BNST), a region known for 
modulating anxiety behavior. Furthermore, Missig et al. have reported an increase in 
PACAP expression in neurons in the central nucleus of the amygdala. This region has 
been reported to represent a merging of pathways for pain, emotion and stress. Together, 
these results suggest PACAP is a regulator of behavior, anxiety, stress and pain (Missig 
et al., 2014).  
1.25 PACAP and vascular smooth muscle 
PACAP’s key function in the cardiovascular system is the modulator of vascular 
tone (Warren et al., 1991, Lenti et al., 2007, Schytz et al., 2009, Schytz et al., 2010b, 
Chan et al., 2011, Syed et al., 2012, Erdling et al., 2013, Koide et al., 2014, Edvinsson, 
2015). The general function of PACAP in the arterial blood vessels is to induce 
vasodilation.  
1.25.1 PACAP and the cranial circulation: PACAP is released from the trigeminal 
sensory and parasympathetic nerves that innervate the walls of cranial arteries to produce 
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vasodilation. Additionally, PACAP has been shown to co-localize with other endogenous 
vasoactive neurotransmitters such as CGRP in trigeminal sensory nerve endings that 
innervate the cerebral and meningeal vascular bed (Baun et al., 2011). PACAP has been 
shown to potently regulate intra- and extra-cranial circulation and has been reported to 
dilate canine, cat, pig and rat (Tong et al., 1993, Uddman et al., 1993b, Anzai et al., 1995, 
Syed et al., 2012, Koide et al., 2014) cerebral arteries.  For example, PACAP induces 
dilation in both ex vivo pressurized rat MMA and cerebellar artery with an EC50 of 1 pM 
and 11 nM respectively, demonstrating a 100-fold increase in potency (Syed et al., 2012). 
These observations suggest involvement of PACAP selective PAC1 receptor in MMA 
versus VPAC1 and VPAC2 receptors in the cerebral arteries.  
1.25.2 Effect of PACAP on cardiac and mesenteric blood vessels: PACAP has been 
demonstrated to induce relaxation of systemic blood vessels. PACAP induces 
vasodilation in isolated, denuded rat and rabbit mesenteric arteries (Huang et al., 1993, 
Wilson and Warren, 1993) indicating the presence of PACAP receptors in vascular 
smooth muscle (VSM) of these arteries.  
 PACAP immunoreactive nerve endings are localized in close proximity to 
vascular smooth muscles in cardiac tissue suggesting that PACAP plays a role in the 
coronary circulation. Indeed, there is evidence that PACAP has vasorelaxant effects in 
rabbit and human coronary arteries (Wilson and Warren, 1993, Chan et al., 2011). 
Further, the EC50 of PACAP in rabbit mesenteric and aortic vascular beds has been 
reported to be ~ 100 nM suggesting involvement of VPAC1 and VPAC2 receptors 




1.25.3 PACAP and the ophthalmic circulation: Retinoprotective effects of PACAP are 
well known and have been established in several disease models including diabetic 
retinopathy and ischemic retinal lesions. It is well established that decreased blood flow 
to the retinal layer can lead to apoptosis of the retinal cells subsequently leading to loss of 
vision. Interestingly, local application of PACAP has been shown to improve functional 
outcome in chronic retinal ischemic injury (Danyadi et al., 2014). Additionally, PACAP 
works synergistically with CGRP to relax ophthalmic arteries in humans supporting the 
vasodilatory role of PACAP in ocular vessels (Dorner et al., 1998). Not surprisingly 
PACAP has been touted as a potential therapeutic target for diabetic retinopathy 
(Marzagalli et al., 2015). 
1.25.3 PACAP and the reproductive system: As the placental circulation has no 
autonomic innervation, hormonal signaling becomes essential in regulating placental 
blood flow (Y and S, 2010). PACAP is one hormone that has been demonstrated to play a 
key role in autocrine/paracrine signaling in placenta. The major source of PACAP in 
placental-tissue are the gonadotrophs and folliculostellate cells (Winters and Moore, 
2011). By causing relaxation of  utero-placental arteries and influencing maternal 
(placental)-fetal blood circulation, PACAP plays an important role in fetal homeostasis 
(Steenstrup et al., 1996).  Furthermore, in adult males, PACAP has been shown to induce 
penile-erection due to its vasorelaxant properties, making it a potential therapeutic target 
in erectile dysfunction (Hedlund et al., 1995). 
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1.25.4 PACAP and the dermal circulation: The vasculature of the skin plays an 
important role in thermoregulation. PACAP contributes to the regulation of dermal blood 
flow by activation of PACAP receptors on arterial smooth muscle cells resulting in 
vasodilation (Warren et al., 1991). For example, the bite of the sand fly (genus: 
lutzomyia, family: Psychodidae) results in swelling of the affected area and vasodilation 
of the dermal blood vessel within the vicinity of the bite due to the action of the PAC1 
selective agonist maxadilan present in the saliva of sand flies.  
1.25.5 PACAP and the pancreatic circulation: PACAP has a biphasic effect on 
pancreatic blood vessels; low concentrations of PACAP (10-11 M to 10-9 M) induce  
vasodilation while concentrations above 10-7 M induce vasoconstriction. The mechanism 
by which PACAP is able to induce this biphasic effect is ambiguous and further studies 
are required, although Bertrand et al. suggest that PACAP selective PAC1 receptors may 
be involved in the vasoconstrictive response (Bertrand et al., 1996). 
1.26 PACAP and disease 
 
PACAP has been implicated in post-traumatic stress disorder (PTSD) and has 
been identified as a biomarker for PTSD in female patients (Ressler et al., 2010). 
Furthermore, a strong correlation has been demonstrated between PTSD patients and 
migraine and PTSD has been implicated as a robust predictor of migraine (Smitherman 
and Kolivas, 2013). Elevated levels of PACAP are implicated in both migraine and 
PTSD, however the mechanism by which PACAP effects vascular smooth muscle in 
PTSD patients is an interesting question that requires further investigation. 
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PACAP is well known for its neuroprotective effects and activation of its 
receptors has been proposed to be therapeutically beneficial for cerebral vasospasm 
following subarachnoid hemorrhage (SAH) (Kaminuma et al., 1998). Moreover, PACAP 
levels in cerebral spinal fluid (CSF) and plasma are reported to be upregulated in patients 
suffering from traumatic brain injury (TBI). High PACAP levels in the CSF may be 
indicative of damage in blood brain barrier and this observation makes PACAP a 
potential biomarker to predict TBI mortality rate. (Bukovics et al., 2014).  
In summary PACAP is a key vasoregulator of several vascular beds and is known 
to exert its effect via the cAMP-PKA pathway. Additionally, PACAP has been 
demonstrated to be a key player involved in several pathophysiological conditions 
including migraine and PTSD. 
1.3 Section 2 
1.31 Role of potassium channels in regulation of arterial tone 
  Potassium channels play a crucial role in regulation of arterial diameter via 
regulation of vascular smooth muscle membrane potential (Brayden, 2002). Under 
physiological conditions, activation of potassium channels results in efflux of K+ from 
the cell, driving the membrane potential to a more negative state towards EK resulting in 
membrane potential hyperpolarization of vascular smooth muscle (VSM) cells. This 
hyperpolarization decreases the open probability of L-type voltage-dependent calcium 
channels (L-VDCC) channels consequently decreasing intracellular Ca2+.  The reduction 
in intracellular Ca2+ leads to smooth muscle relaxation and vasodilation (Nelson and 
Quayle, 1995). Conversely, inactivation of potassium channels leads to membrane 
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potential depolarization and activation of L-VDCC and influx of Ca2+. Ca2+ binds to Ca2+-
binding protein calmodulin (CaM) which in turn interacts and activates myosin light 
chain kinase (MLCK). MLCK then phosphorylates myosin light chain (MLC) resulting in 
increased myosin ATPase activity and activation of the contractile apparatus resulting in 
constriction (Walsh, 1981). Several potassium channels have been demonstrated to 
regulate arterial diameter via regulation of membrane potential including voltage gated 
potassium (Kv) channels, BK channels, inward rectifying potassium (Kir) channels and 
KATP channels (Nelson and Quayle, 1995). 
1.32 Discovery of KATP channels 
 
In 1983, Noma et al. reported the presence of a potassium channel of previously 
unknown description in cardiac myocytes exposed to hypoxic conditions. These channels 
were characterized by inhibition to physiological ATP levels, suggesting a role of these 
channels in energy metabolism and earning them the name of ATP-sensitive potassium 
(KATP) channels (Noma, 1983). Subsequently, KATP channels were discovered to be 
present and playing a key role in glucose homeostasis in pancreatic ß cells. KATP channels 
were determined to be a key regulator in insulin secretion from pancreatic ß cells 
(Ashcroft et al., 1984). In 1989, Standen et al. first described the presence of KATP 
channels in vascular smooth muscle and its role in regulation of vascular smooth muscle 





1.33 Structure of KATP channels 
 
KATP channels are a member of the ATP binding cassette (ABC) protein family 
that includes CFTR (cystic fibrosis transmembrane conductance regulator). As the name 
implies, KATP channels are sensitive to adenosine triphosphate (ATP). ATP (1-3 mM) 
inhibits the openings of these channels (Hayabuchi et al., 2001). Conversely, KATP 
channels are activated by nucleotide diphosphates such as adenosine diphosphate (ADP). 
Thus KATP channels are described as metabolism sensing channels (Nichols, 2006). 
KATP channels are comprised of four Kir6.x channel subunits, forming the ion 
channel pore and four auxiliary sulphonylurea subunits (SURx). Together Kir6x and 
SURx subunits form a functional hetero-octameric channel. There are two Kir6 genes in 
vertebrates (KCNJ8, KIR6.1 and KCNJ11, KIR6.2) and two SUR genes (ABCC.8, SUR1 
and ABCC.9, SUR2) and combinations of different Kir6.x and SURx subunits from 
distinct types of KATP channels. The Kir6x subunits consist of two transmembrane helices 
M1 and M2 connected by an extracellular loop that generates the narrow portions of the 
channel and controls ion selectivity. The SUR subunits contain 17 transmembrane 
regions that are arranged into 3 transmembrane domains TMD0, TMD1, and TMD2. 
SURs contain a NBF1 (nucleotide-binding fold) between TMD1 and TMD2 and a second 
NBF2 after TMD2 for its cytoplasmic interaction with nucleotides (Nichols, 2006) 
(Figure 4). The Kir subunit is responsible for ATP inhibition while the SUR protein is 
responsible for nucleotide diphosphate (NDP) activation. Exogenous KATP potassium 
channel openers (KCO) such as cromakalim and minoxidil sulphate also bind SUR 
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subunit and activate the channel (Nichols, 2006). Additionally, sulphonylurea drugs such 
as glibenclamide and tolbutamide can inhibit this channel (Nichols, 2006). Furthermore, 
the SURx subunits have also been observed to have different binding affinities for ATP, 
ADP and sulphonylurea drugs. For example, it has been previously reported that 
glibenclamide binds to SUR1 subunit with a much higher affinity as opposed to SUR2A 
and SUR2B (Hibino et al., 2010).  Hence splice variants introduce a diverse physiological 
function in different tissue types, consequently providing therapeutic opportunities to 
target specific tissue (Ashcroft et al., 1984, Hibino et al., 2010).  
The molecular constituents for KATP channels differ in different tissue and the 
combination of Kir6x subunits and SURx proteins determines channel characteristics in a 
given tissue. For example, in pancreatic ß cells, Kir6.2 and SUR1 are the dominant 
isoforms, while in cardiac myocytes, Kir6.2 and SUR2A are the major isoforms. In 
vascular smooth muscle, the predominant isoforms are Kir6.1 and SUR2B (D'Arcy et al., 
1985, Nelson and Quayle, 1995, Quayle et al., 1995, Ploug et al., 2008, Hibino et al., 
2010, Ploug et al., 2012). KATP channels can also be modulated by a plethora of 
intracellular signaling molecules including pH and Ca2+, PKA and protein kinase C 
(PKC) and the modulation varies with different compositions of Kir6.x and SURx 
subunits 89. 
1.34 Modulation of KATP channel gating 
 
ATP is an endogenous inhibitor of KATP channels and it exerts its effect by 
binding to a site located on the Kir6x subunit and stabilizing the closed stated of the 
channel (Kajioka et al., 1991).  The activation site of the KATP channel is located on the 
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SURx subunit. Another important means of KATP channel regulation via Gs-coupled 
cAMP-PKA phosphorylation of the channels. The phosphorylation sites include S385 in 
Kir6.1, T633 and S1465 in SUR2B, S1387 in NBF2 of SUR2B. Additionally, Kir6.2 can 
be phosphorylated at T224 by PKA and at T180 by PKC.   The potassium channel 
openers (KCOs) such as cromakalim, pinacidil and diazoxide can also modulate KATP 
channel gating. In SUR2A and SUR2B the binding of the KCOs is between TMD1 and 
TMD2.  Intracellular nucleotides also affect the binding of KCOs. For example, with 
cardiac KATP channels, diazoxide cannot induce channel opening in the absence of ADP 
(Hibino et al., 2010). 
1.35 Membrane trafficking  
 
Only functional hetero-octameric KATP channels are trafficked to the plasma 
membrane. However, Tucker et al., have shown that the truncated form of Kir 6.2ΔC26 
can also produce functional KATP channels in the absence of SUR subunit that can be 
trafficked to the plasma membrane. In smooth muscle the trafficking of KATP channels 
involves the activity of PKCε as demonstrated by Jiao et al. They showed that PKCε 
dependent-inhibition of vascular KATP channels is via caveolin-dependent internalization 
resulting in reduction of surface expression of the channels both in HEK and native 
vascular smooth muscle cells (Jiao et al., 2008).  
1.36 Physiological relevance of KATP channels in pancreas, heart and brain 
 
Pancreas: In pancreas KATP channels are found in pancreatic ß cells, which are 
responsible for secretion of insulin. The molecular subunits of pancreatic KATP channels 
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consist of Kir6.2 and SUR1 (Inagaki et al., 1996). The critical role of KATP channels in 
pancreas is to couple blood glucose level to insulin secretion. As blood glucose levels 
increase in pancreatic ß cells, ATP also rise. Elevated ATP causes inhibition of KATP 
channel activity, which results in membrane potential depolarization, and opening of L-
VDCC. The Ca2+ influx initiates the fusion of the vesicles containing insulin to the 
membrane for release. Polymorphism in Kir6.2 and SUR1 has been associated with 
hypoglycemia and diabetes in humans. Furthermore, KATP channels are also present in the 
glucagon-secreting α-cell and may be involved in secretion of these hormones. 
Additionally, over-activity of the KATP channels in the pancreatic ß cells can result in 
suppression of insulin release resulting in type 2 diabetes. Sulphonylurea drugs like 
glibenclamide are used to treat this condition. Glibenclamide inhibits KATP channels thus 
increasing the open probability of L-VDCC and increase in intracellular Ca2+ and 
consequently increase insulin secretion (Koster et al., 2005). 
Heart: The molecular composition of KATP channels in the heart is Kir6.2 and SUR2A. 
Cardiac KATP channels have been proposed to play a critical role in ischemia 
preconditioning, which is the phenomenon wherein transient ischemic events engage 
protective signaling pathways that involve a variety of second messengers including 
PKC. This preconditioning event can protect the heart from prolonged ischemic insults 
and can be mimicked by openers of KATP channels (Tomai et al., 1999). However, the 
detailed mechanisms mediating ischemia preconditioning and cardioprotection is unclear. 
(Cohen et al., 2000, Iliodromitis et al., 2007).  
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Brain: Like the heart, KATP channels in neurons have been proposed to play a neuro-
protective role under pathophysiological conditions (Ballanyi, 2004). The brain 
represents approximately 2% of the body and yet it consumes 20% of the total energy 
(Raichle and Gusnard, 2002). This high metabolic demand of the brain generally keeps 
neuronal KATP channels closed. However, during injurious events such as ischemia and 
hypoxia mammalian neurons are known to undergo depolarization, leading to excessive 
intracellular calcium and death. Several studies have demonstrated that during hypoxia 
KATP channels are activated as a protective mechanism causing hyperpolarization and 
prevention of cell death (Ballanyi, 2004, Nichols, 2006).  
1.37 Physiological relevance of KATP channels in vascular smooth muscle 
In many vascular beds, KATP channels play an important role in regulation of the 
membrane potential in vascular smooth muscle and vascular diameter. Vascular KATP 
channels consist predominantly of Kir6.1 subunit and sulphonylurea receptor SUR2B 
isoforms (Hibino et al., 2010).  
PKA and KATP channels: KATP channels are important targets for elevated cAMP and in 
turn PKA in vascular smooth muscle myocytes (Wellman et al., 1998). PKA 
phosphorylates serine 385 (S385) residue located on Kir 6.1 and two sites on SUR2B 
subunit, residue serine 1465 (S1465) and threonine 633 (T633) leading to channel 
activation (Quinn et al., 2004).  Furthermore, Hayabuchi et al. have stipulated that basal 
PKA activity is involved in tonic regulation of KATP channels in isolated rat mesenteric 
myocytes. They report that in the presence of physiological ATP concentration (1 mM) 
vascular KATP channels are active due to basal PKA activity. Using whole cell patch 
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clamp Hyabuchi et al. demonstrated that in the presence of low concentration of ATP (0.1 
mM), pinacidil (KATP channels agonist)-induced currents were not inhibited by PKA 
inhibitor (Rp-cAMP). Conversely, at the physiological concentration of ATP (1 mM), 
pinacidil-induced currents become susceptible to inhibition by Rp-cAMP. Interestingly, 
this evidence suggests that tonic PKA activity is dependent on physiological ATP levels, 
which can affect the cAMP production in the cell (Hayabuchi et al., 2001). Additionally, 
in the presence of calyculin A (phosphatase 1 (PP1) and (PP2A) inhibitor), KATP channel 
currents are significantly increased, indicating a critical balance between phosphorylation 
and dephosphorylation in mesenteric myocytes. Dart et al. have shown that KATP 
channels are compartmentalized along with AC in a signaling pocket on the smooth 
muscle membrane by caveolae (a membrane invagination of the plasma membrane 
associated with cholesterol-binding protein caveolin) (Sampson et al., 2004, Sampson et 
al., 2007).  
Epac and KATP channels: Exchange protein activated by adenylyl cyclase (Epac) is a 
novel protein activated by cAMP that has recently emerged as a regulator of vascular 
smooth muscle diameter independent of PKA activity (Purves et al., 2009). Epac has 
been shown to regulate K+ channels in vascular smooth muscle; it inhibits KATP channels 
in a calcium dependent manner and activates BK, small-conductance calcium activated 
potassium (SK) channels, and intermediate-conductance calcium activated potassium 
(IK) channels. Dart et al. have reported that Epac transiently increased intracellular Ca2+ 
levels in rat aortic myocytes resulting in activation of calcium-dependent phosphatase 2B 
(PP2B, calcinuerin) and dephosphorylation of PKA-dependent phosphorylated KATP 
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channels (Roberts and Dart, 2014). In a separate study, Dart et al. further investigated the 
effect of this transient increase in Ca2+ by Epac. They found that the synthetic Epac 
agonist 8-pCPT acetocymethyl ester (8-pCPT-AM) increased the frequency of Ca2+ 
sparks from ryanodine receptors (RyRs) in vascular smooth muscle cells resulting in 
activation of BK channels and membrane potential hyperpolarization. The evidence 
presented by Dart et al. in these studies suggest that Epac may have two distinct roles in 
regulation of vascular tone depending on the vascular bed involved (Roberts et al., 2013, 
Roberts and Dart, 2014).  
PKC and KATP channels: In vascular smooth muscle cells, PKC is associated with 
vasoconstriction. Activation of PKC can result in phosphorylation and inhibition of KATP 
channels leading to depolarization and vasoconstriction (Aziz et al., 2014). Several 
vasoconstrictors can work via the PKC pathway to induce vasoconstriction in vascular 
smooth muscle cells including endothelin, neuropeptide Y, phenylephrine, histamine, 
serotonin (Wakatsuki et al., 1992, Aziz et al., 2014) and angiotensin-ІІ (Dart, 2014). 
Angiotensin-ІІ is part of the renin-angiotensin system, which causes vasoconstriction and 
has been implicated in hypertension. Angiotensin receptors (AT1) are Gq/11 coupled and 
activate phospholipase C (PLC) that in turn activates PKC(Dart, 2014). Additionally, 
several studies suggest that the novel PKC isoform protein kinase C epsilon (PKCε) is 
responsible for the inhibition of KATP channels in vascular smooth muscle. Jiao et al. have 
demonstrated that activation of PKCε results in a caveolin-dependent internalization of 
the KATP channels (Jiao et al., 2008).  Hayabuchi et al. proposed that not only is 
angiotensin-ІІ working via PKC to decrease KATP channel activity; they further suggest 
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that angiotensin-ІІ also inhibits PKA activity. AT1 receptors can also be Gi/o-coupled and 
their activation will decrease cAMP production hence effectively reducing PKA 
activation (Nelson and Brayden, 1993, Hayabuchi et al., 2001).  
1.38 KATP channels and Pathophysiology  
Excessive activation of KATP channels in vascular smooth muscle can result in 
hypotension and conversely, excessive KATP channel inhibition can lead to hypertension 
and ischemia (Nelson and Quayle, 1995, Brayden, 2002).  In addition, during hypoxia 
there is dilation of coronary and small mesenteric arteries (Daut et al., 1990).  Duat et al., 
suggest that under hypoxic conditions there is a decrease in ATP and an increase in ADP 
production resulting in opening of coronary KATP channels, triggering hyperpolarization 
and vascular smooth muscle relaxation and increased blood flow to the heart and 
cardioprotection. KATP channels have also been shown to play a role in acidosis. During 
hypoxic and ischemic events, the extracellular pH drops. Ishizaka et al. have 
demonstrated that this drop in pH causes activation of KATP channels in the coronary 
arteries resulting in vasodilation (Ishizaka and Kuo, 1996). However, the mechanism by 
which KATP channels are activated due to a drop in pH remains unclear. Ishzaka et al., 
suggested that it could be due to either decreased ATP levels arising from high metabolic 
demand or release of adenosine (Nelson and Brayden, 1993, Kleppisch and Nelson, 
1995b, a). 
Previous published studies using either global Kir6.1 or SUR2 knock out mice 
demonstrated that the mice were hypertensive and prone to sudden death due to coronary 
vasospasm (Chutkow et al., 2002, Miki et al., 2002, Kakkar et al., 2006). Yet, when 
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SUR2B was selectively reintroduced in smooth muscle of the coronary vasculature, the 
lethal phenotype persisted. Further, when SUR2A was reconstituted in cardiac myocytes 
the mortality rate decreased suggesting that it may not be vascular KATP channels that are 
critical in influencing the lethal phenotype in global knock out of either Kir6.1 or SUR2. 
However, recently an extensive study done by Aziz et al. using Kir6.1 conditional 
knockout mice revealed that vascular KATP channels are essential for vascular reactivity 
and blood pressure (Aziz et al., 2014).  This study provided evidence that mice with 
Kir6.1 conditional knockout do not display sudden death due to coronary vasospasm yet, 
they still have a hypertension phenotype, indicating that Kir6.1 is the molecular pore-
forming subunit in vascular smooth muscle (Kakkar et al., 2006).  
In summary, KATP channels have been demonstrated to play crucial roles 
physiological and pathophysiologic conditions in vascular smooth muscle. Activation of 
KATP channels has been demonstrated to relax vascular blood vessels and has been shown 
to be beneficial in pathophysiological conditions like hypertension (Aziz et al., 2014, 
Aziz et al., 2015). Conversely, activation of this channel in the cranial vessels has been 
demonstrated to induce headache and to play a role in migraine headache (D'Arcy et al., 
1985, Sterndorff and Johansen, 1988, Ploug et al., 2008, Ploug et al., 2012).  
1.39 Research Objectives of the Present Work 
 
The objectives of the study were: 1) to decipher the mechanism involved in 
PACAP-induced vasodilation of the MMA and 2) to determine the tonic regulation of 
MMA diameter by basal KATP channel activity. We hypothesized that PACAP induces 
dilation in the MMA via activation of vascular KATP channels. Additionally, we show that  
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KATP channels are tonically active in the MMA and are contributing to MMA diameter 







Figure 1: Schematic representation of MMA involvement in migraine headache. 1) 
Noxious stimuli the cause release of the neuropeptide PACAP and other vasodilators 
neuropeptides that bind to their respective receptors on MMA. 2) Binding of the 
neuropeptides to their respective receptors results in vasodilation. 3) Distention of the 
artery is proposed to activate afferent sensory neurons (mechanism unknown). 4) The 









Figure 2: Location of middle meningeal artery. Modified 











Figure 3: Illustration of the proposed pathway of glibenclamide-induced MMA 
constriction. Tonic PKA-dependent activation of KATP channels results in membrane 
potential hyperpolarization and MMA dilation. Bottom: KATP inhibition by glibenclamide 











Figure 4: Schematic representation of the structural subunits of KATP channels. 
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 Migraine is a debilitating neurological disorder characterized by mild to severe 
headache that is often accompanied by aura and other neurological symptoms.  Among 
proposed mechanisms, dilation of the dural vasculature especially the middle meningeal 
artery (MMA) has been implicated as one component underlying this disorder.  Several 
regulatory peptides from trigeminal sensory and sphenopalatine postganglionic 
parasympathetic fibers innervating these vessels have been implicated in the process 
including pituitary adenylate cyclase activating polypeptide (PACAP).  Although PACAP 
has been well described as a potent dilator in many vascular beds, the effects of PACAP 
on the dural vasculature are unclear.  In the current study, we examined the ability of 
PACAP to dilate MMAs that were isolated from rats and pressurized ex vivo.  PACAP38 
potently dilated pressurized MMAs with an EC50 of 1 pM.  The PAC1 receptor 
antagonist, PACAP(6-38), abolished MMA dilation caused by picomolar concentrations 
of PACAP.  In contrast, cerebellar arteries isolated from the brain surface were ~1000-
fold less sensitive to PACAP than MMAs.  Although cerebellar arteries expressed 
transcripts for all three PACAP receptor subtypes (PAC1, VPAC1 and VPAC2 receptors) 
by RT-PCR analyses, MMA demonstrated only PAC1 and VPAC2 receptor expression.  
Further, multiple variants of the PAC1 receptor were identified in the MMA.  The 
expression of PAC1 receptors and the high potency of PACAP to induce MMA 




 Migraine is one of the most prevalent contributors to the global burden of mental 
disorders (Collins et al. 2011). It is a complex episodic neurological disorder 
characterized by intense unilateral pulsating headaches that may last hours to days, which 
may be accompanied by aura, nausea, photophobia, phonophobia and other neurological 
symptoms (Asghar et al. 2011). Although the causes and mechanisms underlying 
migraine are multifactorial and remain poorly understood, one likely contributing factor, 
first proposed decades ago (Ray et al. 1940), involves dilation of the dural vasculature.  
Subsequent investigations have implicated trigeminal sensory and/or sphenopalatine 
parasympathetic postganglionic neuronal signaling as a contributor to the experience of 
migraine pain (Mayberg et al. 1981; Brain et al. 1985; Lassen et al. 2002; Olesen et al. 
2009; Schytz et al. 2009; Schytz et al. 2010; Asghar et al. 2011; Amin et al. 2012).   In 
one current model, enhanced neurotransmitter/neuropeptide release causes MMA dilation 
leading to sensitization of the trigeminal sensory neuronal fibers innervating the MMA 
that contributes to the perception of pain (Goadsby et al. 1993).  Bioactive neuropeptides 
may participate in all of these events and one prototypic neuroregulator in migraine is 
calcitonin gene-related peptide (CGRP).  CGRP is a potent vasodilator (Brain et al. 
1985), is highly expressed in dorsal root/trigeminal sensory and sphenopalatine 
autonomic ganglia neurons, has been localized to perivascular nerve terminals 
(McCulloch et al. 1986), and has been shown to induce migraine-like headaches 
indistinguishable from spontaneous migraine attacks (Lassen et al. 2002). Notably, 
magnetic resonance angiography (MRA) imaging studies have correlated MMA 
42 
 
vasodilation following exogenous CGRP administration with headache onset to further 
implicate roles for neurally-mediated vasodilation in migraine (Asghar et al. 2011). 
 Similar to CGRP, more recent studies have also implicated pituitary adenylate 
cyclase activating polypeptide (PACAP) signaling in migraine.  PACAP is a 
neurotransmitter and neurotrophic peptide in the secretin, glucagon and vasoactive 
intestinal peptide (VIP) superfamily and shares some G protein coupled receptor 
selectivity with VIP (Vaudry et al. 2009). PACAP binds potently and specifically to the 
PAC1 receptor which may be coupled to multiple intracellular signaling cascades; by 
contrast, both PACAP and VIP bind with near equal affinity to VPAC1 and VPAC2 
receptors coupled principally to adenylyl cyclase.  Among its many functions, PACAP 
has prominent roles in nociception and like CGRP, causes relaxation of vascular and 
respiratory smooth muscle (Seki et al. 1995).  The peptide is highly expressed in diverse 
central and peripheral nervous system tissues, including sensory and autonomic ganglia, 
and appears co-localized with CGRP for concomitant release upon neuronal stimulation 
(Csati et al. 2012).  Hence PACAP shares expression and regulatory parallels with 
CGRP, and significantly, recent clinical studies have shown that intravenous infusion of 
PACAP can produce MMA vasodilation and induce headache in both migraineurs and 
healthy subjects (Schytz et al. 2009; Amin et al. 2012).  Further, the administration of the 
serotonin 5-HT1B and 5-HT1D receptor agonist sumatriptan, frequently used to treat 
migraine headaches, attenuated both PACAP-induced MMA vasodilation and headache 
pain.  These studies indicate that PACAP signaling causes MMA dilation that may 
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contribute to the etiology of migraine (Amin et al. 2012) and represent an important 
therapeutic target to aid migraneurs.   
 Despite the immediate relevance to migraine, PACAP signaling in the MMA has 
not been well characterized.  In the current study, we examined the effects of PACAP on 
isolated segments of MMA using pressurized artery myography.  Compared to other 
intracranial vessels, the high potency of PACAP and the expression PACAP receptors in 
the MMA appear unique, suggesting that the MMA vasodilatory responses to 




Isolation of middle meningeal and cerebellar arteries 
All experiments and protocols were conducted in accordance with the Guide for the Care 
and Use of Laboratory animals (NIH Pub. No. 85-23, revised 1996) and approved by the 
Institutional Animal Use and Care Committee of the University of Vermont.  Sprague-
Dawley rats (males, 300-350 g; Charles River Laboratories, Saint Constant, QC, Canada) 
were euthanized by decapitation under deep isoflurane anesthesia.  The brain and calvaria 
were carefully removed and placed in ice-cold 3-(N-morpholino) propanesulfonic acid 
(MOPS)-buffered saline solution containing (in mM): 145 NaCl, 5 KCl, 1 Mg SO4, 2.5 
CaCl2, 1 KH2PO4, 0.02 EDTA, 3 MOPS, 2 pyruvate, 5 glucose and 1% bovine serum 
albumin (pH 7.4).  For MMA isolation, the dura mater was gently removed from the 
calvaria under a dissection microscope (Figure 1A).   To enable a comparison of the 
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MMA to pial arteries, cerebellar arteries were dissected from the brain using iris scissors.  
The MMA and cerebellar artery are both innervated by trigeminal sensory nerves 
(Simons et al. 1988; Goadsby et al. 1993).  
Pressurized artery myography 
Middle meningeal and cerebellar arteries were cannulated onto glass micropipettes 
mounted in a 5 mL myograph chamber (Figure 1B) and intravascular pressure was 
adjusted using a pressure servo-controller and a peristaltic pump (Living Systems 
Instruments, St, Albans, VT) as previously described (Ishiguro et al. 2002; Nystoriak et 
al. 2011).  Arteries were continuously superfused with warmed artificial cerebral spinal 
fluid (aCSF; 37 °C, in mM: 125 NaCl, 3 KCl, 18 NaHCO3, 1.25 NaH2PO4, 1 MgCl2, 2 
CaCl2 and 5 glucose, aerated with 5% CO2, 20% O2, 75% N2, pH: 7.35-7.40).  Changes 
in vessel diameter were measured by video edge detection (Living Systems 
Instrumentation, St Albans, VT) using Windaq data acquisition software (Dataq 
Instruments; Akron, OH).  Following equilibration (1 h), arterial viability was evaluated 
by brief exposure to 60 mM KCl (< 2 min; isosmotic replacement of NaCl with KCl in 
aCSF).  Only arteries that demonstrated a constriction representing a decrease in diameter 
of 50 % or greater were used in subsequent studies.  Pressure-induced constriction is 
expressed as a percent decrease of the fully dilated diameter of individual arteries at the 
same intravascular pressure.  These values were obtained by using the following 
equation:  % constriction = (DP-DA)/DP · 100 where DP = the (passive) diameter of the 
artery in Ca2+-free aCSF containing the vasodilators diltiazem (100 µM) and forskolin (1 
µM), and DA = the (active) diameter of the artery in Ca2+-containing aCSF.  Dilations in 
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response to PACAP38 and VIP are expressed as a percent reduction in the level of 
arterial constriction.  The values were obtained using the following equation: % dilation = 
(DV-DA)/(DP-DA) · 100 where DV = arterial diameter in the presence of vasodilator, DA 
= the active diameter of the artery prior to addition of vasodilator, and DP = the passive 
diameter of the artery.  The 38 amino acid form of PACAP, referred to as PACAP38 
(Miyata et al. 1989), was used in all experimental series.   The concentrations of 
PACAP38 or VIP that caused half maximal vasodilation (EC50) were calculated from 
individual concentration response curves using Graphpad Prism 5 software (Graphpad 
software, Inc. La Jolla, CA).  PACAP38, VIP and related peptides (American Peptide 
Sunnyvale, CA) were prepared as 100 µM stock in deionized water; aliquots were stored 
at -80 °C.  All aliquots were diluted to their final concentrations immediately before use 
and were administered to arteries by bath superfusion (5 mL/min flow rate) for a 
minimum of 20 minutes. 
MMA and cerebellar artery PACAP receptor transcript expression 
Total RNA extracted from isolated MMAs and cerebellar arteries using RNA STAT-60 
total RNA isolation reagent (Tel-test, Friendswood, TX) was reverse-transcribed to 
cDNA using SuperScript First-Strand synthesis system (Invitrogen, Carlsbad, CA) as 
previously described (Nystoriak et al. 2009).  To detect mRNA expression of PACAP 
receptor subtypes, semiquantitative RT-PCR was performed using primer sets for PAC1, 
VPAC1 and VPAC2 receptor transcripts; amplification of the same templates for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as an internal control 
(Table 1).  To examine vessel expression of PAC1 receptor splice variants, amplification 
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using primers flanking the alternative splice site within the third cytoplasmic loop of the 
PAC1 receptor was performed as previously described (Braas et al. 1999).  Amplification 
of single-stranded cDNA was performed in a 13 µL reaction volume consisting of 15 mM 
Tris-HCl, pH 8.0, containing 50 mM KCl, 2.5 mM MgCl2, 200 µM deoxynucleotide 
triphosphates, 0.5 µM primers, 0.5 µL of cDNA template and 0.3 U AmpliTaq Gold 
DNA polymerase (Applied Biosystems, Norwalk, CT) with the following cycling 
parameters: (1) initial denaturation and enzyme activation 95 °C, 10 min; (2) denaturation 
and enzyme activation 94 °C,1 min; annealing, primer specific (Table 1), 1 min; 
extension 72 °C, 1 min (32 - 40 cycles); and (3) final extension, 72 °C; 10 min.  For 
PAC1 receptor variant identification, the amplified cDNA product was subjected to 
diagnostic restriction enzyme digestion as previously described (Braas et al. 1999).  The 
amplified products were resolved on 2% agarose gel and visualized by UV illumination 
following ethidium bromide staining.   
Statistics 
  Data are expressed as mean ± SEM and analyzed by Student’s unpaired t-test.  





Isolated middle meningeal arteries (MMA) exhibit pressure-induced myogenic tone. 
 Small diameter arteries and arterioles isolated from a variety of vascular beds, 
including those supplying blood to the heart and brain, constrict in response to increases 
in intravascular pressure (Bayliss 1902; Johnson 1980).  In the cerebral circulation, 
pressure-induced constriction, also termed myogenic tone, plays an important role in the 
regulation of cerebral artery diameter (Nelson et al. 1995; Ishiguro et al. 2002; Nystoriak 
et al. 2011).  To evaluate myogenic tone in freshly isolated MMA segments, changes in 
arterial diameter were examined in response to step-wise increases in intravascular 
pressure.  At 10 mmHg, MMA diameter in aCSF was 45.8 ± 5.2 µm, representing a 
constriction of 39.1 ± 5.8 percent decrease from the maximally dilated diameter of 75.5 ± 
4.6 µm obtained in Ca2+-free aCSF containing the vasodilators diltiazem (100 µM) and 
forskolin (1 µM).  The level of myogenic tone increased as intravascular pressure was 
elevated, reaching a constriction of 62.9 ± 8.4 % at 120 mmHg (Figure 2).  At the 
physiologically relevant pressure of 40 mmHg, myogenic tone represented a constriction 
of 49.1 ± 10 %.  These data demonstrate that isolated MMA exhibit pressure-induced 
myogenic tone. Subsequent experimental series were performed using isolated MMAs 




Picomolar concentrations of PACAP38 dilate pressurized MMAs via activation of 
PAC1 receptors. 
 The ability of PACAP to induce MMA dilation ex vivo, is unclear.  To date, 
studies of PACAP-induced responses in isolated MMA segments have examined changes 
in isometric force generation in unpressurized arteries pre-contracted with exogenous 
vasoconstrictors (Baun et al. 2011).  To examine the impact of PACAP on ex vivo 
pressurized MMAs exhibiting myogenic tone, increasing concentrations of PACAP38 or 
VIP (0.1 pM to 100 nM) were added to the superfusate bathing MMAs held at an 
intravascular pressure of 40 mmHg (Figure 3A). PACAP38 potently dilated MMA with 
an EC50 of 1 pM (n = 4).  In marked contrast, VIP was approximately 1000-fold less 
potent dilator of MMA (EC50: 1.4 nM, n = 4).  As an example, 3 pM PACAP38 caused 
MMA dilation of 60.3 ± 15.1 % of tissue maximum, whereas 3 pM VIP did not 
significantly alter arteriolar diameter (Figures 3B, C). Based on the differential potency 
of PACAP38 and VIP binding to PACAP receptor subtypes (Harmar et al. 2012), we 
hypothesized that MMA dilation to picomolar concentrations of PACAP38 are mediated 
via activation of PAC1 receptors.  Consistent with this concept, MMA dilation to 3 pM 
PACAP38 was abolished by the PAC1 receptor antagonist PACAP (6-38) (Harmar et al. 
2012) (Figure 4A, B).  Interestingly, MMA dilation to 1000-fold higher concentrations of 
PACAP38 (i.e. 3 nM) were not abolished, but were reduced by approximately 50 % 
(Figure 4C-E), consistent with higher concentrations of PACAP38 causing activation of 
PAC1 receptors as well as VPAC1 and/or VPAC2 receptors.  These data demonstrate that 




Nanomolar, but not picomolar, concentrations of PACAP38 dilate pressurized 
cerebellar arteries. 
 Intracranial cerebral arteries are innervated by sensory trigeminal nerves 
containing PACAP, but appear to contribute little to migraine symptoms (Asghar et al. 
2011; Amin et al. 2012).  To examine whether PACAP dilates pressurized cerebral 
arteries with an efficacy similar to that observed in MMA, cerebellar arteries were 
cannulated and studied ex vivo.  In contrast to MMAs, 3 pM PACAP38 did not alter 
cerebellar artery diameter (n = 4, Figure 5 A, C).  However, 1000-fold higher 
concentrations of PACAP38 (3 nM) did significantly dilate cerebellar arteries (34 ± 12 
%, n = 4). The EC50 value of PACAP-induced cerebellar dilation was 11 nM (n = 6).  
Similarly, VIP caused cerebellar artery dilation at nanomolar, but not picomolar, 
concentrations (Figure 5 B, C; EC50 = 6 nM, n = 3).  These data demonstrate that PACAP 
is considerably more potent vasodilator of MMA compared to cerebellar arteries, 
suggesting that the PACAP- and VIP-induced vasodilation in cerebellar arteries is likely 
mediated by a VPAC receptor subtype.  
MMA and cerebellar arteries express different PAC1 and VPAC receptor subtypes. 
 PACAP and VIP share receptor subtypes; the PAC1 receptor is specific for 
PACAP peptides while VPAC1 and VPAC2 receptors bind VIP and PACAP with similar 
affinities.  Differential PACAP receptor expression may contribute to the disparity in the 
sensitivity of MMA and cerebellar arteries to PACAP. To establish PACAP/VIP receptor 
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expression in MMA and cerebellar arteries, semiquantitative PCR studies were 
performed using primers unique to each receptor transcript, as described in previous work 
(Braas et al. 1999).  Interestingly, only PAC1 and VPAC2 receptor transcripts were 
detected in MMA; there was little to no VPAC1 receptor expression in MMA.  By 
contrast, all three PACAP/VIP receptor subtypes (PAC1, VPAC1 and VPAC2 receptors) 
were identified in cerebellar arteries (Figure 6A).   
 There are multiple PAC1 receptor isoforms from alternative splicing of Hip 
and/or Hop cassettes in the receptor gene corresponding to the G protein interactive sites 
in the third cytoplasmic loop, which are important for downstream activation of signaling 
cascades (Spengler et al. 1993).  When PAC1 receptor variant transcript analyses were 
performed using primers flanking the third cytoplasmic loop, MMA and cerebellar 
arteries not only expressed the PAC1null receptor (neither Hip nor Hop, Figure 6B, 303 
bp band) but also the one cassette variant (Hip or Hop, Figure 6B, 387 bp band).  
Furthermore, the relative abundance of the one cassette variant was much greater in the 
MMA than the cerebellar artery.  As the Hip and Hop cassettes are both 84 bp, the one 
cassette 387 bp amplified product could not distinguish the specific PAC1 receptor splice 
variant expressed in MMA.  However, restriction enzyme digestion can be diagnostic 
(Braas et al. 1999) and digestion of the 387 bp band with Blp I generated the 292 bp 
products consistent with the expression of the PAC1Hop receptor variant in MMA 
(Figure 6C).  While the PAC1null receptor is predominantly coupled to adenylyl cyclase, 
the PAC1Hop receptor variant can be potently coupled to multiple intracellular signaling 
cascades including adenylyl cyclase, phospholipase C, MAPK and Akt (Braas et al. 
51 
 
1999).  The expression and coordinate signaling downstream of both PAC1 receptor 
variants in MMA may have engendered the potent PACAP vasodilatory responses; 
maladaptions of the same PACAP/PAC1 receptor signaling pathways in MMA, by 
contrast, may be a contributing factor to migraine. 
2.5 Discussion 
 
 Migraine is one of the leading contributors to the global burden of mental and 
neurological disorders.  The few therapeutic options are often unsatisfactory and hence an 
understanding of the underlying mechanisms and the identification of new clinical targets 
remain important goals for effective treatments.  From the many proposed causes, the 
neurovascular component in migraine has remained a viable mediator especially in light 
of the recent data using high resolution magnetic resonance angiography (MRA) 
techniques (Asghar et al. 2011).   In humans infused with the well studied 
sensory/autonomic vasodilator CGRP peptide, the resulting migraine attacks correlated 
temporally and spatially with middle meningeal and middle cerebral artery dilation.  The 
arterial dilations were bilateral when the headaches were bilateral and unilateral on the 
corresponding side when uni-hemispheric headaches were presented.  Further, treatments 
with sumatripans to ease the peptide-induced migraines always resulted in vessel 
constriction.  These studies appear to supplant earlier Doppler studies which failed to 
correlate vascular changes with migraine (Zwetsloot et al. 1993).  Although these studies 
do not address definitive mechanisms, the results do implicate cranial vascular dynamics 
in the presentation of migraine.  Among intracranial and extracranial arteries, the 
meningeal artery vasodilatory responses were better correlated with headache onset and 
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treatments, and considered to be particularly significant as dural afferent nociceptor 
sensitization appears central to pain generation in migraine attacks (Burstein et al. 2005). 
 PACAP peptides behave as neurotransmitters and neurotrophic peptides in the 
central and peripheral nervous systems with diverse activities in neuroendocrine 
development and function.  PACAP peptides are highly expressed in nociception sensory 
dorsal root and trigeminal ganglion neurons, and in autonomic systems regulating 
vasodilatory control; hence the effects of PACAP parallel those for CGRP in facilitating 
migraines.  PACAP38 infusions in in vivo and ex vivo preparations cause intra- and 
extracranial artery vasodilation and can induce migraine-like attacks in normal subjects 
and migraineurs (Schytz et al. 2009; Amin et al. 2012).  As in other physiological 
systems, the PACAP-elicited responses can be long lasting which may be one of the 
distinguishing characteristics for PACAP-induced headache pain (Amin et al. 2012).  
Interestingly, while the related VIP peptide can also produce marked dilation in many 
arterial vessels, it induces only modest headache and no migraine-like attacks (Hansen et 
al. 2006; Rahmann et al. 2008) suggesting the selective expression and activation of the 
shared PAC1/VPAC receptors in the different cranial arterial systems. 
 Yet despite the unequivocal abilities for PACAP to instill migraine, the relative 
roles of PACAP and VIP in migraine, and whether specific PAC1/VPAC receptor 
subtype expression and function in the different cranial arteries can underlie the distinct 
PACAP/VIP vasodilatory and migraine responses are still very much unclear.  Some of 
the variability observed in the in vivo infusion studies may have stemmed from 
PACAP/VIP-mediated endothelial cell activation of nitric oxide pathways, rapid peptide 
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degradation in the circulation, the poor ability for peptides in general to cross the blood 
brain barrier, and in the case of rodents, the presence of anesthetics during the course of 
the studies.  The putative selectivity of the available receptor agonists and antagonists 
may have contributed to the uncertainties, and the ex vivo isometric force studies may 
have been complicated by the use of high concentrations of reagents  including  
prostaglandin F2α and serotonin to precontract the unpressurized wire-mounted vessels.   
 From these considerations, the use of a pressurized arteriograph system offers a 
number of advantages in characterizing PACAP and VIP vasodilatory responses.  The 
pressurized arterial vessels develop myogenic tone in the absence of exogenous 
vasoconstrictors, are extremely sensitive and responsive to regulatory dynamics (Dunn et 
al. 1994; Nelson et al. 1995), and obviate the need for drug-induced arterial 
precontraction, which can potentially dampen the peptide vasodilatory effects.  The 
MMA possesses the ability to autoregulate its blood flow and pressure intrinsically 
(Michalicek et al. 1996); hence the pressurized MMA myography preparation presents a 
physiologically relevant means to examine PACAP-induced effects. 
 Using these preparations, the current studies demonstrated potent PACAP38 
effects on MMA diameter.  In contrast to previous isometric force myograph studies 
which suggested little or no PACAP effects on MMA contractility (Baun et al. 2011), 
subpicomolar concentrations of PACAP38 reproducibly dilated pressurized MMAs ex 
vivo.   Picomolar PACAP concentrations maximally dilated the MMA to 50 - 60% of 
passive diameter; high nanomolar PACAP concentrations had little additional 
vasodilatory effects.  VIP also dilated MMA but only at nanomolar peptide 
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concentrations. The picomolar potency of PACAP has been well described for several 
physiological systems including protection from ischemia in the brain and potentiation of 
glucose induced insulin release in pancreatic beta cells (Yamada et al. 2004; Dejda et al. 
2011). These differential PACAP/VIP response profiles in the MMA differed from those 
observed for cerebellar arteries in which PACAP38 and VIP appeared equipotent in 
inducing vasodilations at nanomolar concentrations.   
 The higher potency of PACAP compared to VIP in the MMA suggest PAC1 
receptor activation in the vasodilatory responses.  Both PAC1 and VPAC2 receptor 
transcripts were identified in the MMA; interestingly, VPAC1 receptor expression in the 
MMA was not detected, which varied with previous work (Boni et al. 2009).  Diagnostic 
PCR and restriction digests identified PAC1null and PAC1Hop1 receptor isoforms in the 
MMA which may have allowed second messenger coupling not only to adenylyl cyclase 
but to other intracellular cascades to potently stimulate MMA dilation.  PACAP(6-38) 
pretreatment blocked the PACAP38 responses in the MMA and although PACAP(6-38) 
may antagonize both PAC1 and VPAC2 receptors (Dickinson et al. 1997) to obfuscate 
clear identification of the relevant receptor subtype in the PACAP-induced responses, the 
apparent differential potencies observed for PACAP38 and VIP were consistent with 
PAC1 receptor-mediated vasodilation in the MMA.  These results appear consistent with 
previous interpretations implicating PAC1 receptors in migraine (Olesen et al. 2009; 
Schytz et al. 2009; Schytz et al. 2010).   Unlike the MMA, however, the cerebellar 
arteries exhibited expression for all three PACAP/VPAC receptor subtypes.  The 
apparent equipotency of PACAP38 and VIP in eliciting cerebellar artery vasodilation 
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(Figure 5) implicate VPAC receptor signaling.  These results were in good agreement 
with previous observations implicating VPAC1 receptors in cerebellar artery vasodilation 
(Fahrenkrug et al. 2000). 
 In summary, the pressurized myograph preparations in the current study 
demonstrated differences between PACAP and VIP in eliciting MMA and cerebellar 
artery vasodilation which may be notable with respect to migraine physiology.  The very 
high potency for PACAP38 to elicit and sustain MMA vasodilation suggested that even 
very modest levels of neuropeptide release and receptor activation may be sufficient to 
mediate migraine pain.   As suggested in previous studies, the physiological and 
molecular analyses demonstrated differential PAC1/VPAC receptor expression profiles 
among the cranial vessels examined.  The high potency of PACAP38, the expression of 
PAC1 receptor subtype and isoforms, and the abilities for the antagonist PACAP(6-38) to 
block PACAP-induced MMA dilation all implicated PAC1 receptor signaling in MMA 
vasodilation. As MMA vasodilatory dynamics well correlated with migraine onset and 
abatement in humans, PACAP/PAC1 receptor regulation of the MMA may be a crucial 
component to the development of migraine attacks.  This action of PACAP on MMA 
contrasts with PACAP/VIP dilation of cerebellar arteries which appeared to be mediated 
via VPAC1 receptor activation.  Together with the human PACAP infusion studies, these 
observations in sum suggest that PACAP and PAC1 receptor signaling may be a potential 
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Figure 1: Preparation of rat middle meningeal artery (MMA) for arteriograph 
studies. A) Rat MMA embedded in the dura matter prior to dissection.  Arrows indicate 
the MMA region typically used for ex vivo studies.  B) Isolated rat MMA cannulated on 
glass micropipettes mounted in an arteriograph chamber.  Both ends of MMA were tied 
by suture thread, and the artery pressurized to 40 mmHg.  Arterial diameter was 
measured using video edge detection and recorded using data acquisition software 
(details in Materials and Methods).  One graduation of scale (e.g. 0 to 1) represents 100 





Figure 2: Pressure-induced myogenic tone in isolated rat middle meningeal arteries 
(MMAs).  A) Diameter measurements of isolated rat MMA obtained in response to step-
wise increases in intravascular pressure from 10 mmHg to 120 mmHg.  Squares with 
solid line represent active diameter measurements obtained in artificial cerebral spinal 
fluid (aCSF) (n = 4).  Circles with dashed line represent maximally dilated (passive) 
diameter measurements obtained from the same arteries in Ca2+-free aCSF containing the 
vasodilators diltiazem (100 µM) and forskolin (1 µM).  B) Pressure-induced constriction 
(myogenic tone) in rat MMAs superfused with aCSF ex vivo.  Constriction is expressed 





Figure 3: Low picomolar concentrations of PACAP, but not VIP, dilate isolated 
pressurized rat middle meningeal arteries (MMAs). A) Cumulative concentration 
response curves of PACAP and VIP obtained from rat MMAs pressurized to 40 mmHg 
ex vivo.  Arteries were exposed to aCSF containing each concentration of PACAP38 or 
VIP for 20 minutes. Dilation to PACAP38 or VIP are expressed as percentage of 
maximum dilation obtained in the presence of Ca2+-free aCSF containing 100 µM 
diltiazem and 1 µM forskolin.  P<0.05 by unpaired t-test, n = 4.  B, C) Diameter 
recordings of an isolated MMA treated with aCSF containing a single concentration (3 
pM) of PACAP38 (B) and VIP (C).  At the end of the experiment, maximally dilated 
diameter was obtained in the presence of Ca2+-free aCSF containing 100 µM diltiazem 




Figure 4: Block of picomolar PACAP-induced dilation of isolated pressurized 
middle menigeal artery (MMA) by the PAC1 receptor antagonist PACAP(6-38). A-
D) Diameter recordings from isolated MMAs obtained in the absence (A, C) and 
presence (B, D) of the PAC1 antagonist, PACAP(6-38).  Arteries, pressurized to 40 
mmHg, were treated with either 3 pM PACAP38 (A, B) or 3 nM PACAP38 (C, D).  
Maximum dilation (passive) was obtained by treatment with 100 µM diltiazem and 1 µM 
forskolin in Ca2+-free aCSF.    E) Summary data of PACAP38-induced dilation in the 
absence or presence of PACAP(6-38).  PACAP(6-38) abolished 3 pM PACAP38-induced 
vasodilation, but caused only partial inhibition of 3 nM PACAP38-induced vasodilation 
in rat MMAs (n = 4 each).  Diameter changes by PACAP38 treatment were expressed as 
percentage of maximum dilation. * P<0.05 vs PACAP-induced vasodilation in the 




Figure 5: Nanomolar, but not picomolar, concentrations of PACAP38 and VIP 
dilate pressurized cerebellar arteries. A) Diameter recording obtained from pressurized 
rat cerebellar artery treated with PACAP38. PACAP38 induced dilation at 3 nM, but not 
3 pM.  Maximum dilation was obtained using a combination of 100 µM diltiazem and 1 
µM forskolin in Ca2+-free aCSF (passive).  B) Diameter recording obtained from 
pressurized rat cerebellar artery treated with VIP. VIP induced dilation at 3 nM, but not 3 
pM.  Maximum dilation was obtained using a combination of 100 µM diltiazem and 1 
µM forskolin in Ca2+-free aCSF (passive).  C) Summarized data of PACAP38 and VIP 
treatment in rat cerebellar arteries.  PACAP38-induced diameter changes are expressed as 





Figure 6: PACAP receptor transcripts are differentially expressed in rat middle 
meningeal and cerebellar arteries. Total RNA from rat MMA and cerebellar arteries 
were reverse transcribed for semiquantitative PCR analyses of PAC1 (413 bp), VPAC1 
(323 bp) and VPAC2 (396 bp) receptor transcript expression.  A) Unlike cerebellar artery 
preparations which demonstrated mRNA for all three receptor subtypes (right panel, n = 
5), the MMA appeared to express only PAC1 and VPAC2 receptor transcripts (left panel, 
n = 5).   B)  To examine whether there were differences in PAC1 receptor isoform 
expression levels between the two arteries, primers flanking the third cytoplasmic loop 
were employed in the PCR studies.  While cerebellar arteries appeared to possess 
predominantly the PAC1null receptor isoform (right panel, neither Hip nor Hop; 303 bp), 
the MMA expressed near equal levels of the PAC1null (303 bp) and the one-cassette 
PAC1 receptor variant (387 bp; left panel).  Each lane represents an independent sample 
replicate. Amplification of the same templates for GAPDH demonstrates approximate 
equal sample input.  C) The specific one-cassette PAC1 receptor variant could be 
identified by diagnostic restriction digest; isolation of the MMA 387 bp PAC1 receptor 
band followed by Blp I restriction enzyme incubation resulted in amplicon digestion to a 
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Pituitary adenylate cyclase activating polypeptide (PACAP) is a potent vasodilator of 
numerous vascular beds, including cerebral arteries.  Although PACAP-induced cerebral 
artery dilation is suggested to be cyclic AMP (cAMP)-dependent, the downstream 
intracellular signaling pathways are still not fully understood.  In this study, we examined 
the role of smooth muscle K+ channels and hypothesized that PACAP-mediated increases 
in cAMP levels and protein kinase A (PKA) activity result in the coordinate activation of 
ATP-sensitive K+ (KATP) and large-conductance Ca2+-activated K+ (BK) channels for 
cerebral artery dilation.  Using patch-clamp electrophysiology, we observed that PACAP 
enhanced whole-cell KATP channel activity and transient BK channel currents in freshly 
isolated rat cerebellar artery myocytes.  The increased frequency of transient BK currents 
following PACAP treatment is indicative of increased intracellular Ca2+ release events 
termed Ca2+ sparks.  Consistent with the electrophysiology data, the PACAP-induced 
vasodilations of cannulated cerebellar artery preparations were attenuated by 
approximately 50% in the presence of glibenclamide (a KATP channel blocker) or 
paxilline (a BK channel blocker).  Further, in the presence of both blockers, PACAP 
failed to cause vasodilation.  In conclusion, our results indicate that PACAP causes 
cerebellar artery dilation through two mechanisms: 1) KATP channel activation and 2) 





 Pituitary adenylate cyclase activating polypeptide (PACAP) is a peptide that is 
highly conserved over species and widely distributed in the brain and peripheral organs.  
While acting as a neurotransmitter and neurotrophic peptide in the central and peripheral 
nervous systems (reviewed in Vaudry et al. 2009), PACAP is also a potent vasodilator 
(Warren et al. 1992; Vaudry et al. 2009; Syed et al. 2012).  PACAP-induced vasodilation 
has been observed in various vascular beds including coronary arteries (Bruch et al. 1997; 
Dalsgaard et al. 2003), pulmonary arteries (Cheng et al. 1993), mesenteric arteries 
(Wilson et al. 1993) and cerebral arteries (Tong et al. 1993; Anzai et al. 1995).  For 
example, in vivo treatment of PACAP via an open cranial window resulted in brain pial 
artery dilation in newborn pigs (Tong et al. 1993), and intracisternal administration of 
PACAP caused dose-dependent canine basilar artery dilation detected by angiography 
(Seki et al. 1995).  Further, in ex vivo studies, PACAP caused concentration-dependent 
relaxation of isolated canine basilar arteries (Anzai et al. 1995; Seki et al. 1995), cat 
cerebral arteries (Uddman et al. 1993), rabbit posterior cerebral arteries (Dalsgaard et al. 
2003), rat middle cerebral arteries (Erdling et al. 2013) and rat intracerebral arterioles 
(Anzai et al. 1995).  This vasodilatory effect is, at least in part, a direct effect of PACAP 
on arterial smooth muscle cells.  PACAP binds to three types of receptors; PAC1, 
VPAC1 and VPAC2 (Vaudry et al. 2009; Harmar et al. 2012), and all three receptors are 
expressed in cerebral artery smooth muscle cells (Syed et al. 2012; Erdling et al. 2013).  
Binding of PACAP to PACAP receptors increases production of adenosine 3’, 5’-cyclic 
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monophosphate (cAMP) (Tong et al. 1993; Vaudry et al. 2009) in arterial myocytes 
which likely accounts for the mechanism of PACAP-induced cerebral artery dilation. 
 Increased cAMP production and subsequent activation of cAMP-dependent 
protein kinase (protein kinase A, PKA) can produce vasodilation by several mechanisms 
including activation of smooth muscle K+ channels (Nelson et al. 1995b; Wellman et al. 
1998).  Potassium channels play an important role in the regulation of smooth muscle 
membrane potential, intracellular Ca2+ concentration and arterial diameter; activation of 
smooth muscle K+ channels causes membrane potential hyperpolarization, decreased 
open-state probability of voltage-dependent Ca2+ channels and reduced intracellular Ca2+ 
concentration resulting in vasodilation (Standen et al. 1989; Nelson et al. 1995b; Standen 
et al. 1998).  Dilations induced by a number of endogenous vasoactive substances such as 
calcitonin gene-related peptide (CGRP) have been shown to result from increased ATP-
sensitive K+ (KATP) channel currents via mechanisms involving adenylyl cyclase 
activation, increased cAMP production and PKA activation (Nelson et al. 1990; Quayle 
et al. 1994; Kleppisch et al. 1995a; Wellman et al. 1998).  Similarly, KATP channel 
blockers were able to partially inhibit PACAP-induced vasodilation in coronary and 
pulmonary arteries, suggesting that PACAP may also activate KATP channels (Bruch et al. 
1997; Bruch et al. 1998).   
 Stimulated cAMP/PKA activity however, can also augment the frequency of 
transient large-conductance Ca2+-activated K+ (BK) channel currents (previously referred 
to as spontaneous transient outward currents or STOCs) following intracellular Ca2+ 
spark events (Nelson et al. 1995a; Wellman et al. 2003).  Transient outward BK currents 
71 
 
occur as a result of increases in intracellular Ca2+, called Ca2+ sparks, and represent an 
important physiological vasodilatory pathway in cerebral arteries (Nelson et al. 1995a; 
Wellman et al. 2003).  Ca2+ sparks are transient and localized Ca2+ increases resulting 
from the opening of a small cluster of ryanodine-sensitive Ca2+ channels (ryanodine 
receptors, RyRs) located on the sarcoplasmic reticulum (SR).  These localized increases 
in intracellular Ca2+ lead to activation of nearby BK channels on the plasma membrane 
(transient outward BK currents), resulting in smooth muscle membrane potential 
hyperpolarization and vasodilation (Nelson et al. 1995a; Wellman et al. 2003).  
Considering that the treatment of cerebral artery myocytes with cAMP analogues or 
adenylyl cyclase activators (to elevate intracellular cAMP levels) can increase the 
frequency and amplitude of transient outward BK currents (Porter et al. 1998; Wellman et 
al. 2001; Hayoz et al. 2007), we hypothesized that PACAP-induced increases in cAMP 
can also activate the Ca2+ spark/transient outward BK current pathway to promote 
cerebral vasodilation.  
 Because of its vasodilatory, neurotrophic and neuroprotective effects, PACAP has 
been examined in animal models as possible treatments for cerebral vasospasm after 
subarachnoid hemorrhage (Kaminuma et al. 1998) and ischemic stroke (Reglodi et al. 
2000; Ohtaki et al. 2006).  However, despite its therapeutic potential, the detailed 
intracellular signaling mechanisms involved in PACAP-induced cerebral artery dilation 
are not fully understood.  In this study, we have examined the vasodilatory mechanisms 
of PACAP, focusing specifically on the role of smooth muscle K+ channels in freshly 
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isolated rat superior cerebellar arteries.  Our results indicate that activation of both KATP 
and BK channels contribute to PACAP-induced cerebral artery dilation. 
3.3 Methods 
 
Measurements of KATP currents and transient outward BK currents 
 All experiments and protocols were performed in accordance with the Guide for 
the care and Use of Laboratory animals (eighth edition, 2011) and were approved by the 
Institutional Animal Care Committee of the University of Vermont.  Male Sprague-
Dawley rats (300-350g; Charles River Laboratories, Saint Constant, QC, Canada) were 
euthanized by decapitation under deep pentobarbital anesthesia.  The brain was carefully 
removed and superior cerebellar arteries were isolated in ice cold artificial cerebrospinal 
fluid (aCSF: 125 mM NaCl, 3 mM KCl, 18 mM NaHCO3, 1.25 mM NaH2PO4, 1 mM 
MgCl2, 2 mM CaCl2, and 5 mM glucose, aerated with 5 % CO2, 20 % O2, 75 % N2, pH 
7.35–7.40).   
 Arterial myocytes were enzymatically isolated using a previously described 
protocol (Ishiguro et al. 2005; Koide et al. 2007; Koide et al. 2011).  Briefly, arteries 
were incubated in a solution containing papain (0.3 mg/mL papain, 0.7 mg/mL 1,4-
dithioerythriol) for 17 min at 37 °C, and then in collagenase solution (0.7 mg/mL 
collagenase type F, 0.3 mg/mL collagenase type H,  0.1 mM CaCl2) for 20 min at 37 °C.  
Enzyme solutions were made using a glutamate-containing isolation solution (GIS: 55 
mM NaCl, 5.6 mM KCl, 80 mM L-glutamic acid-Na, 2 mM MgCl2, 2 mM CaCl2, 10 mM 
HEPES, and 10 mM glucose; pH 7.3).  Finally, arteries were washed three times (10 
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minutes each wash) in GIS containing 2 mM CaCl2 on ice then gently triturated into 
individual myocytes using a fire-polished Pasteur pipette. 
 Using the conventional whole cell patch clamp configuration, KATP currents were 
recorded in freshly isolated cerebellar arterial myocyte at room temperature (Wellman et 
al. 1999).  The bath solution contained 134 mM NaCl, 6 mM KCl, 1 mM MgCl2, 1.8 mM 
CaCl2, 10 mM glucose and 10 mM HEPES (pH 7.4).  The “140 mM K+” bath solution 
was made by iso-osmotic replacement of NaCl with KCl.  The pipette solution contained 
107 mM KCl, 1.0 mM MgCl2, 1.9 mM CaCl2, 10 mM HEPES, 5 mM EGTA, 25 mM 
KOH (pH 7.2 adjusted with KOH, free Ca2+ ~100 nM).  On the day of the experiment, 
0.1 mM Na2ATP, 0.1 mM NaADP and 0.1 mM LiGTP were freshly added into an aliquot 
of pipette solution.  KATP currents were recorded at -60 mV.  After a stable baseline was 
obtained, the extracellular solution was changed from “6 mM K+” bath solution to “140 
mM K+” solution.  PACAP was treated by superfusation into the bath in the presence of 
140 mM K+. 
 Transient outward BK currents were measured using the perforated whole-cell 
patch-clamp technique at room temperature (Wellman et al. 2002; Koide et al. 2011). The 
bath solution contained 134 mM NaCl, 6 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM 
glucose and 10 mM HEPES (pH 7.4).  Patch pipettes (8-10 MΩ) were filled with a 
pipette solution that contained 110 mM K+-aspartate, 30 mM KCl, 10 mM NaCl, 1 mM 
MgCl2, 10 mM HEPEs, 0.05 mM EGTA and 0.2 mM amphotericin B (pH 7.2).  
Transient outward currents were recorded at -40 mV.  PACAP was treated by bath 
superfusation.  Recordings were analyzed using Mini Analysis 6.0.3 software 
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(Synaptosoft, Inc., Decatur, GA, USA) to determine transient BK current amplitude, 
frequency, rise time (time from 10 % to 90 % of the peak), decay time (time from 90% to 
37 % of the peak) and half-width (time at 50% of the peak).  The threshold for current 
peak detection was set at two and half times the single channel amplitude of the BK 
channel; 5.0 pA at -40 mV (Perez et al. 2001).  
Diameter measurements of isolated cerebellar arteries 
 Superior cerebellar arteries were cannulated onto glass micropipettes mounted in 
5 ml myograph chamber and the intravascular pressure was increased using a servo 
controller and a peristaltic pump (Living Systems Instruments, St. Albans, VT) as 
previously described (Ishiguro et al. 2002; Nystoriak et al. 2011; Koide et al. 2012).  The 
arteries were continuously superfused with aCSF warmed at 37°C.  Luminal diameter 
was measured and recorded using video edge detection (Living Systems Instrumentation, 
St Albans, VT) and WinDaq data acquisition software (Dataq Instruments; Akron, OH).  
Following a 30 minute equilibration period at 20 mmHg, arteries were briefly exposed to 
60 mM KCl-aCSF (<2 min; iso-osmotic replacement of NaCl with KCl) to test their 
viability. Only arteries that exhibited constriction of 50 % or more to 60 mM KCl-aCSF 
were included for study.  Following an additional 30 minutes, intraluminal pressure was 
increased to 60 mmHg.  Over the course of approximately 1 hour, arteries constricted to 
the increase in intravascular pressure, i.e. developed pressure-induced myogenic tone.  
Once arterial diameter was stabilized at 60 mmHg, PACAP (3 nM) was superfused into 
the chamber in the absence and presence of K+ channel blocker(s).  Percent constriction 
in response to elevation of intravascular pressure was determined using the following 
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equation: [(DP−DA)/DP]×100; where DP = the (passive) diameter of the artery in Ca2+-
free aCSF containing the vasodilators diltiazem (100 µM) and forskolin (1 µM), and DA 
= the (active) diameter of the artery in Ca2+-containing aCSF.  Dilation responses to 
PACAP are expressed as a reduction in arterial constriction using the following equation: 
% dilation = [(DV–DA)/(DP–DA)]×100, where DV = arterial diameter in the presence of 
vasodilator, DA = the active diameter of the artery prior to addition of vasodilator, and 
DP = the passive diameter of the artery. All aliquots of compounds used in the study were 
diluted to their final concentrations immediately before use and were administered to 
arteries by bath superfusion (5 mL/min flow rate) for a minimum of 10 min.  
 
Chemicals 
PACAP was obtained from American Peptide Company (Sunnyvale, CA).  All other 
compounds were purchased from Sigma-Aldrich (St. Louis, MO). 
 
Statistics 
Data are expressed as mean ± SEM. Comparisons between multiple groups were 
analyzed by one-way ANOVA followed by post hoc comparison of means using Tukey 
test.  Student’s paired t-test was used to compare data between two groups.  Statistical 






PACAP activates KATP channels in freshly isolated rat cerebellar artery myocytes. 
Several endogenous vasodilators (e.g. CGRP, adenosine) linked to increased adenylyl 
cyclase activity have been shown to activate KATP channels in arterial smooth muscle 
cells (Nelson et al. 1990; Quayle et al. 1994; Kleppisch et al. 1995a; Kleppisch et al. 
1995b; Wellman et al. 1998).  To examine whether PACAP can increase KATP channel 
activity in freshly isolated cerebellar artery myocytes, membrane K+ currents were 
measured by patch clamp electrophysiology.  Here, recording conditions using the 
conventional whole-cell configuration were designed to optimize KATP currents and 
minimize BK and voltage-dependent K+ (KV) channel activity (e.g. 0.1 mM ATP, 0.1 
mM ADP and 5 mM EGTA in intracellular pipette solution; holding potential of -60 mV) 
(Wellman et al. 1998).  In symmetrical (intracellular and extracellular) 140 mM K+, the 
K+ equilibrium potential (EK) predicted by the Nerst equation is 0 mV.  Thus, at a holding 
potential negative to EK, e.g. -60 mV, KATP channel activation will cause K+ ions to move 
into the cell creating an inward electrical current (Quayle et al. 1994; Kleppisch et al. 
1995b; Wellman et al. 1998).  As shown in figure 1A, treatment of a cerebral artery 
myocyte with the synthetic KATP channel opener, pinacidil (10 µM), caused a significant 
increase in inward K+ current that was inhibited by the KATP channel blocker, 
glibenclamide (10 µM).  Using similar recording conditions, PACAP (3 nM) treatment 
also caused an increase in inward K+ current (figure 1B).  This data suggests that PACAP 




PACAP increases the frequency of transient outward BK currents in rat cerebellar 
artery myocytes 
An increase in the frequency of smooth muscle transient outward BK currents represents 
another potential mechanism involved in PACAP-induced cerebral artery dilation.  
Transient BK currents represent the coordinated opening of up to 100 individual BK 
channels in regions of the cell membrane (≈ 1 % of the total cell surface area) exposed to 
brief local increases in Ca2+ sparks (Wellman et al. 2003). Treatment of vascular smooth 
muscle cells with either a cAMP analogue, an adenylyl cyclase activator (e.g. forskolin) 
or endogenous vasodilators that elevate intracellular cAMP levels causes an increase in 
the frequency of Ca2+ spark-induced transient BK currents triggered by Ca2+ sparks 
(Porter et al. 1998; Wellman et al. 2001).  Considering that PACAP can potently increase 
intracellular cAMP levels, activation of the Ca2+ spark/transient BK current pathway may 
also contribute to PACAP-induced cerebral artery dilation.  To examine this hypothesis, 
we directly measured transient BK currents in freshly isolated cerebellar artery myocytes 
using the whole-cell perforated patch configuration of the patch clamp technique.   In this 
experimental series, cells were held at the physiological membrane potential of -40 mV in 
an extracellular (bath) solution containing 6 mM K+.  Spontaneous transient outward BK 
currents were observed in these cells and PACAP (3 nM) significantly increased the 
frequency of these events by approximately 50% (from 1.38 ± 0.47 Hz to 2.02 ± 0.51 Hz; 
n = 6 cells from 3 animals, figure 2A and 2B).  Although PACAP markedly increased the 
transient BK current frequency, the amplitude of these events was not dramatically 
altered by PACAP treatment (before treatment: 14.71 ± 2.11 pA, after PACAP treatment: 
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17.49 ± 2.98 pA, figure 2C).  Further, the temporal characteristics of transient BK 
currents were similar before and after PACAP treatment: rise-time10-90% (msec): 7.94 ± 
0.85 / 7.28 ± 0.30; decay time90-37% (msec): 25.03 ± 3.84 / 23.57 ± 4.16; half-width 
(msec): 30.33 ± 3.21 / 31.33 ± 3.34 (n = 6 cells from 3 animals, before / after PACAP 
treatment, respectively).  In summary, these data demonstrate that PACAP increased the 
frequency of Ca2+ spark-mediated transient BK currents in isolated rat cerebellar artery 
myocytes. 
PACAP-induced cerebellar artery dilation involves activation of both BK and KATP 
channels 
The above studies indicate that PACAP can increase the activity of both BK and KATP 
channels in freshly isolated cerebellar artery myocytes.  Next, the functional contribution 
of these K+ channels in PACAP-induced dilation was examined in isolated and 
pressurized rat superior cerebellar arteries.  At a physiological intravascular pressure of 
60 mmHg, arteries superfused with aCSF developed pressure-induced constriction 
(myogenic tone) representing a 23.0 ± 1.3 % decrease in diameter (n = 19 from 19 
animals).  At 60 mmHg, the average diameter of cerebellar arteries in aCSF with 
myogenic tone was 191.1 ± 7.5 µm compared to a fully-dilated diameter of 247.2 ± 7.5 
µm obtained in Ca2+-free aCSF containing diltiazem (100 µM, a voltage-dependent Ca2+ 
channel blocker) and forskolin (1 µM).  PACAP (3 nM) caused significant dilation (52.2 
± 10.7% of maximal dilation), increasing the average arterial diameter from 189.8 ± 9.1 
µm to 220.8 ± 14.0 µm (n = 4 from 4 animals, figure 3A and 3E).  To examine whether 
KATP channel activation (shown in figure 1B) contributes to PACAP-induced cerebellar 
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artery dilation, arteries were treated with the KATP channel blocker, glibenclamide (10 
µM).  Gibenclamide treatment alone, did not change arterial diameter (187.0 ± 14.7 µm 
and 185.8 ± 16.4 µm, in the absence and presence of glibenclamide, respectively, n = 4 
from 4 animals), suggesting minimal basal KATP channel activity in these arteries.  
However, in the presence of glibenclamide, the PACAP-induced dilations were 
significantly attenuated (approximately 50% of maximal dilation with PACAP alone vs 
22.6 ± 11.8 % of maximal dilation in PACAP + glibenclamide; n = 4 from 4 animals, 
figure 3B).  This data indicates that PACAP-induced vaosodilation is partially caused by 
KATP channel activation.   
 We next examined if activation of the Ca2+ spark/transient BK current pathway 
also plays a role in PACAP-induced cerebellar artery dilation.  To inhibit this pathway, 
arteries were treated with the BK channel blocker, paxilline (1 µM), which alone 
constricted arteries in aCSF from 204.0 ± 13.4 µm to 174.4 ± 14.7 µm, an approximate 
15% decrease in diameter on top of myogenic tone (fig. 3C, note paxilline-induced 
vasoconstriction before PACAP application; fully-dilated diameter: 262.6 ± 11.1 µm, n = 
7 from 7 animals).  This paxilline-induced vasoconstriction is consistent with previous 
studies demonstrating that the Ca2+ spark/transient BK current pathway plays an 
important negative-feedback role in the regulation of cerebral artery myogenic tone 
(Nelson et al. 1995a; Koide et al. 2011; Nystoriak et al. 2014).  The PACAP-induced 
vasodilation was significantly attenuated in the presence of paxilline (approximately 50% 
maximal dilation with PACAP alone vs 14.8 ± 2.6% of maximal dilation in PACAP + 
paxilline; n = 7 from 7 animals), suggesting that the Ca2+ spark/transient BK current 
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pathway is also involved in PACAP-induced dilation (figure 3C and 3E).  Thus, when 
applied separately, blockers of KATP channels (glibenclamide) and BK channels 
(paxilline) both decreased PACAP-induced dilations by approximately 50%.  
Interestingly, the combined treatment of arteries with both glibenclamide and paxilline 
abolished PACAP-induced cerebellar artery dilation.  In the presence of glibenclamide 
and paxilline, arterial diameter before and after PACAP treatment was 174.0 ± 21.9 µm 
and 163.5 ± 23.7 µm, respectively (n = 4 from 4 animals, figure 3D and 3E).  In 
summary, these data indicate that PACAP causes cerebellar artery dilation through 
activation of both KATP and BK channels. 
3.5 Discussion 
 
Here we demonstrate that two distinct mechanisms contribute to PACAP-induced 
cerebellar artery dilation; activation of KATP channels and BK channels.  The involvement 
of smooth muscle KATP and BK channels in cerebral artery dilations caused by PACAP 
(depicted in figure 4) is supported by our following observations: 1) PACAP increased 
KATP channel activity in isolated rat cerebellar artery myocytes, 2) PACAP also increased 
the frequency of cerebral artery smooth muscle transient BK currents, 3) Individual 
application of either the KATP channel blocker (glibenclamide) or the BK channel blocker 
(paxilline) significantly attenuated PACAP-induced cerebral artery dilation (~ 50 % 
attenuation in the presence of either blocker) and 4) the combined treatment of arteries 




In vascular smooth muscle, functional KATP channels are thought to be composed 
of four Kir 6.1 pore-forming subunits encoded by the gene KCNJ8 and four SUR2B 
accessory subunits encoded by the gene ABCC9 (Flagg et al. 2010).  KATP channels of 
arterial myocytes are activated by a variety of endogenous vasodilators such as CGRP 
(Nelson et al. 1990; Quayle et al. 1994; Kleppisch et al. 1995a; Kleppisch et al. 1995b; 
Wellman et al. 1998) as well as cAMP analogs and cell dialysis with the catalytic subunit 
of PKA (Quayle et al. 1994; Wellman et al. 1998).  PKA-mediated phosphorylation of 
serine and threonine residues within the nucleotide binding folds of SUR2B subunits is 
thought to promote ADP binding to increase channel activity (Quinn et al. 2004; Shi et al. 
2007; Flagg et al. 2010).  In this study, we demonstrate that PACAP, another endogenous 
vasodilator known to stimulate adenylyl cyclase activity (Tong et al. 1993; Vaudry et al. 
2009), can activate KATP channels in rat cerebral artery smooth muscle.  As shown Figure 
1, activation of KATP currents by pinacidil and PACAP evoked inward membrane 
currents at -60 mV using intracellular and extracellular solutions that both contained 140 
mM K+.  However, with physiological K+ concentrations (e.g. extracellular K+ ≈ 5.4 mM; 
intracellular K+ ≈ 140 mM), KATP channel activation causes outward membrane currents 
in isolated arterial smooth muscle cells and membrane potential hyperpolarization and 
vasodilation of intact arteries (Standen et al. 1989; Masuzawa et al. 1990; Quayle et al. 
1994; Kleppisch et al. 1995b; Nelson et al. 1995b; Bruch et al. 1997; Bruch et al. 1998). 
Consistent with our electrophysiological recordings, PACAP-induced cerebellar artery 
dilation was significantly attenuated by the KATP channel blocker glibenclamide (Figure 
3).  Together, these data indicate that KATP channel activation contributes to PACAP-
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induced vasodilation in rat cerebellar arteries likely via activation of the cAMP/ PKA 
pathway. 
 In addition to activation of KATP channels, increased intracellular cAMP and PKA 
activation can also enhance the Ca2+ spark/transient BK current signaling pathway to 
promote cerebral artery dilation (Porter et al. 1998; Wellman et al. 2001).  Our data now 
shows that PACAP increases the frequency of transient BK currents in rat cerebellar 
artery myocytes (figure 2) and that BK channel activity is involved in PACAP-induced 
cerebral artery dilation (figure 3).  Previous investigations have revealed three 
mechanisms that can contribute to PKA-mediated increased Ca2+ spark/BK channel 
activity.  First, PKA can phosphorylate ryanodine receptors (RyRs), which are the 
sarcoplasmic reticulum (SR) Ca2+ release channels responsible for Ca2+ spark generation 
(Marx et al. 2000; Wehrens et al. 2006).  Phosphorylation of RyRs by PKA increases 
their Ca2+ sensitivity resulting in elevated frequencies of Ca2+ sparks and Ca2+-spark 
induced transient BK currents.  Secondly, phosphorylation of phospholamban (PLB) can 
also contribute to PKA-mediated cerebral artery dilation (Simmerman et al. 1998; 
Wellman et al. 2001).  Phospholamban is a regulatory protein that when bound to SR 
Ca2+-ATPase (SERCA) causes a decrease in SERCA activity and reduced filling of the 
SR with Ca2+.  Phosphorylation by PKA causes PLB to dissociate from SERCA, leading 
to disinhibition of SERCA activity and elevation of SR Ca2+ load (Simmerman et al. 
1998; Wellman et al. 2001) that can increase Ca2+ spark/BK current frequency and 
amplitude (ZhuGe et al. 1999).  Lastly, PKA can increase BK channel activity via direct 
channel phosphorylation (Minami et al. 1993; Perez et al. 1994; Porter et al. 1998).  
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Phosphorylation of BK channels by PKA causes a leftward-shift in the voltage-activation 
relationship (toward more negative membrane potential) without changing single channel 
conductance (Perez et al. 1994).  Further, it has been suggested that cAMP can directly 
increase the open-state probability of BK channels based on the observation of increased 
single BK channel activity by application of cAMP to the intracellular side of excised 
membrane patches (Minami et al. 1993).  A direct cAMP/PKA-mediated increase in BK 
channel activity would likely cause an increase in the amplitude of transient BK currents 
without altering Ca2+ spark frequency.  In the present study, we demonstrate that PACAP 
increases the frequency, but not amplitude, of transient BK currents in isolated rat 
cerebellar artery myocytes.  This observation is consistent with PACAP causing an 
increase in Ca2+ spark frequency rather than directly altering the voltage-sensitivity of 
plasma membrane BK channels.   Future studies are required to confirm the involvement 
of the cAMP/PKA pathway in PACAP-induced cerebral artery dilation, as well as the 
specific proteins involved in the observed increase in Ca2+ spark/transient BK current 
frequency.  However, we clearly demonstrate the functional importance of the Ca2+ 
spark/BK channel pathway in PACAP-induced cerebellar artery dilation.  As illustrated 
in figure 3, the BK channel blocker, paxilline, attenuated PACAP-induced vasodilation 
by approximately ~50%.  Furthermore, the combined treatment of cerebral arteries with 
paxilline and the KATP channel blocker, glibenclamide, completely inhibited cerebral 
artery responses to PACAP.  These data suggested that two pathways, activation of KATP 
and BK channels, are independent and both play an important role in PACAP-induced 
cerebellar artery dilation.  
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 In summary, here we demonstrate that two distinct cell signaling mechanisms 
contribute to PACAP-induced dilation in rat cerebellar arteries; KATP channel activation 
and enhanced BK channel activity.  Both mechanisms likely involve activation of the 
cAMP/PKA pathway, however further studies are needed to determine additional details 
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Figure 1: KATP channel currents in rat cerebellar artery myocytes.   A) KATP current 
measurement obtained from an isolated cerebellar artery myocyte.  Whole-cell patch 
clamp recording conditions were used to optimize KATP currents and minimize other BK 
and KV channel currents (e.g. 140 mM K+ in extracellular bath solutions, 0.1 mM ATP 
and 0.1 mM ADP in intracellular pipette solution, -60 mV of holding potential).  The 
synthetic KATP channel opener, pinacidil (10 µM), caused an increase in inward current 
that was inhibited by the KATP channel blocker, glibenclamide (10 µM).  B) Original 
recording of PACAP treatment on inward K+ current using the same recording conditions 







Figure 2: PACAP enhanced transient BK current activity in rat cerebellar artery 
myocytes.  A) Effect of PACAP (3 nM) on transient outward BK currents, showing 
increased frequency, but not amplitude, in rat cerebellar artery myocytes.  Transient BK 
currents were measured at -40 mV.  Expanded traces of transient outward BK currents 
are shown in lower panels.  B and C) Summary data of transient outward BK current 
frequency (B) and amplitude (C).  n = 6 cells from 3 animals.  ** P < 0.01 vs before 





Figure 3: PACAP induced vasodilation is mediated via both KATP and BK channels 
in isolated rat cerebellar arteries. A) Representative trace of PACAP-induced dilation 
of a cerebellar artery. The artery was pressurized to 60 mmHg and treated with PACAP 
(3 nM) by bath superfusion.  B and C) PACAP-induced vasodilation was significantly 
attenuated in the presence of the KATP channel blocker, glibenclamide (10 µM, panel B) 
or the BK channel blocker, paxilline (1 µM, panel C).  D) The combined treatment of 
glibenclamide (Glib) and paxilline (Pax) abolished PACAP-induced cerebellar artery 
dilation.  E) Summary data of PACAP-induced dilations in the absence and presence of 
glibenclamide and paxilline (n = 4-7).  Data are expressed as mean ± SE.  * P < 0.05, ** 






Figure 4: Proposed mechanisms of PACAP-induced vasodilation in rat cerebellar 
artery. AC: adenylyl cyclase, ATP: adenosine tri-phosphate, BK: large-conductance 
Ca2+-activated potassium (K+) channels, cAMP: cyclic adenosine mono-phosphate, KATP: 
ATP-sensitive potassium (K+) channels, PACAP: pituitary adenylate cyclase activating 
polypeptide, PKA: protein kinase A, PLB: phospholamban, RyR: ryanodine receptors, 
SERCA: sarcoplasmic reticulum calcium transport ATPase, SR: sarcoplasmic reticulum, 
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ATP-sensitive potassium (KATP) channels have been suggested to play a crucial 
role in the regulation of membrane potential and diameter in several vascular beds. The 
objective of the current study was to determine if KATP channels are tonically regulating 
middle meningeal artery (MMA) diameter, a vascular bed suggested to be involved in 
migraine headache. Using ex vivo diameter measurements, smooth muscle membrane 
potential measurements and ratiometric calcium measurements, we demonstrate that 
basal KATP channel activity, due to ongoing cyclic AMP-dependent protein kinase (PKA) 
activity, profoundly impacts MMA diameter. 
4.2 Introduction 
 
Potassium channels play a crucial role in regulation of vascular diameter. 
Activation of these channels results in hyperpolarization of the membrane potential (EM) 
towards the equilibrium potential of K+ (EK). The resulting hyperpolarization reduces the 
open-state probability of L-type voltage gated calcium channels, reducing the influx of 
calcium and causing relaxation of vascular smooth muscle.  One key potassium channel 
in vascular smooth muscle is the ATP-sensitive potassium (KATP) channel (Nelson and 
Quayle, 1995). In vascular smooth muscle the predominant KATP channel isoform 
consists of four pore forming Kir 6.1 subunits and four sulphonylurea receptor SUR2B 
subunits (Nichols, 2006). KATP channels are important targets for protein kinase A (PKA) 
in response to increased adenylate cyclase activity in vascular smooth muscle myocytes 
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(Shi et al., 2007). PKA can phosphorylate serine 385 (S385) residue located on Kir 6.1 
subunits and two sites on SUR2B subunits, residue serine 1465 (S1465) and threonine 
633 (T633) (Quinn et al., 2004). Phosphorylation of these sites have been proposed to 
enhance binding of the stimulatory Mg-ADP to the nucleotide binding folds (NBFs) 
leading to activation (Nichols, 2006).  Under physiological conditions, treatment with the 
KATP channel inhibitor, glibenclamide induces constriction in the meningeal vascular bed 
while it induces no effect in mesenteric or brain surface arteries (pial) (Quayle et al., 
1995, Koide et al., 2014).  
In the present study we investigate basal regulation of MMA diameter by KATP 
channels. Our findings indicate that KATP channels are tonically regulating MMA 
diameter. Furthermore, this tonic regulation is mediated by protein kinase A (PKA). 
4.3 Methods 
 
Material, methods and references associated with them are available in supplemental 
information on the JCBFM website. 
4.4 Results 
 
Inhibition of basal KATP channel activity induces MMA constriction 
Involved in setting membrane potential of vascular smooth muscle cells, 
potassium channels, including KATP channels have been described as key regulators of 
resistance artery diameter (Quayle et al., 1997). To explore and establish the role of KATP 
channels in the regulation of MMA diameter, we utilized a pressurized ex-vivo diameter 
measurement technique that has been previously described (Syed et al., 2012).   At an 
97 
 
intravascular pressure of 40 mm Hg, MMA diameter was 54.3 ± 2.4 µm in artificial 
cerebral spinal fluid (aCSF), representing a 40 ± 2 % (n = 30 arteries) constriction 
compared to the fully dilated diameter of 90 ± 3 µm. Treatment with the KATP channel 
inhibitor, glibenclamide (10 µM), caused an additional constriction representing a further 
20 ± 2 % decrease in lumen diameter (Figure 1 A, n = 5). Furthermore, treatment with 
another KATP channel inhibitor, PNU37883 (10 µM), resulted in a similar 
vasoconstriction (20 ± 3 % decrease in diameter, Figure 1 A). In contrast, treatment of 
cerebellar arteries with glibenclamide (10 µM) or PNU37883 (10 µM) did not 
significantly affect diameter (Figure 1 A n = 5). These results suggest that there is basal 
KATP channel activity in MMA, but not in cerebral arteries.  
Inhibition of KATP channels leads to membrane potential depolarization in MMA 
Inhibition of potassium channels leads to membrane potential depolarization and 
vasoconstriction (Brayden et al., 1991). As inhibition of KATP channels causes MMA 
vasoconstriction, we hypothesized that KATP channels are contributing to MMA smooth 
muscle membrane potential. At 40 mmHg, MMA smooth muscle membrane potential 
was -45.4 ± 1.4 mV. Treatment with 10 µM glibenclamide resulted in significant 
membrane potential depolarization to -31.3 ± 2.7 mV (Figure 1 B, n= 4 each), 
representing a change in membrane potential of approximately 14 mV. In comparison, 
cerebellar artery smooth muscle membrane potential was not significantly different in the 
absence (-37.1 ± 0.9 mV) and presence (-36.8 ± 0.8 mV) of glibenclamide (Fig. S 1 A, n 
= 4). This data supports our hypothesis that KATP channels contribute a tonic 
hyperpolarizing influence to MMA smooth muscle membrane potential.  
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Inhibition of KATP channels increases intravascular calcium in MMA smooth muscle 
via L-VDCC 
Given that inhibition of KATP channels induced vasoconstriction and membrane 
potential depolarization, we hypothesized that glibenclamide causes increased Ca2+ influx 
via enhanced activity of L-type VDCCs. To first test this hypothesis, we examined 
glibenclamide-induced changes in arterial wall calcium using the ratiometric calcium 
indicator, Fura 2. Arteries were initially equilibrated at 10 mmHg where the diameter was 
37.8 ± 5.6 µm with an average vascular smooth muscle calcium level of 179 ± 28 nM  
(n=18). At 40 mmHg MMA developed myogenic tone of 18.3 ± 2.9 %, accompanied 
with an increase of arterial wall calcium to 470 ± 50 nM. Treatment with 10 µM 
glibenclamide evoked an average vasoconstriction of 23.4 ± 1.0 % with an increase of 
187.5 ± 77 nM in intracellular calcium corresponding to an increase in Fura-2 
F340/F380-ratio of 0.24 ± 0.03 (Figure 1 C, n = 4).  These data demonstrate that 
inhibition of KATP leads to an increase smooth muscle intracellular calcium. 
 As L-VDCCs play a critical role in development of myogenic tone, the following 
experiments were performed at 10 mmHg to minimize the potentially confounding 
effects of the L-type VDCC inhibitor, diltiazem, on myogenic tone. In the absence of 
diltiazem (100 µM), glibenclamide (10 µM) resulted in vasoconstriction of 21.2 ± 2.6 % 
(Fig. S 2 A and C, n = 13) representing a change in diameter of 14.7 ± 2.1 µm.  However, 
in the presence of diltiazem, the glibenclamide-induced vasoconstriction was abolished 
(Fig. S 2B, n = 5). Together, these results support our hypothesis that increased cytosolic 
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calcium following KATP channel inhibition is due to enhanced activity of L-VDCC in 
MMA smooth muscle.    
Regulation of KATP channels by basal PKA activity in MMA smooth muscle 
Previous studies using the patch clamp technique and isolated rat mesenteric 
artery myocytes have shown that basal KATP activity is dependent on tonic PKA activity 
(Hayabuchi et al., 2001, Sampson et al., 2004, Dart, 2014).  We therefore hypothesized 
that KATP channels in the MMA are being tonically regulated by basal PKA activity. We 
tested this hypothesis by treating MMAs pressurized to 40 mmHg with the PKA inhibitor 
KT5720 (1 µM); this resulted in a vasoconstriction of 25.2 ± 5.2 % (Figure 2 A and B, n 
= 4). In contrast, KT5720 induced no significant vasoconstriction in cerebellar arteries 
(1.9 ± 2.3 %). Furthermore, in the presence of KT5720, glibenclamide (10 µM) did not 
induce any further constriction of MMA (Figure 2 A). These findings suggest that basal 
PKA activity contributes to opening of KATP channels in MMA. Additionally, treatment 
with another PKA inhibitor, H89 (1 µM) resulted in significant membrane potential 
depolarization from -46.8 ± 0.5 mV to 33.5 ± 0.6 mV and  no further depolarization was 
observed with addition of  10 µM glibenclamide  (Fig. 1S C, n = 4). 
Our data indicate that KATP channels are endogenously active in MMA and that 
PKA is responsible for this phenomenon. These findings are consistent with the concept 
that basal PKA activity is contributing to sensitization of KATP channels (Quinn et al., 
2004).  To further explore this possibility, cumulative concentration-response curves to 
the KATP channel agonist, cromakalim, were obtained using both MMA and cerebellar 
arteries. We observed that MMAs were 10-fold more sensitive to cromakalim (EC50 of 
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100 nM) compared to cerebellar arteries (EC50 of 1 µM, Figure 2 C n = 4-5). However, in 
MMA, PKA inhibition with KT5720 (1 µM) resulted in a decrease in cromakalim 
sensitivity (EC50 of 300 nM, Figure 2 C).  
4.5 Discussion 
 
The results presented in this study provide strong evidence of tonic regulation of 
MMA diameter by KATP channels. Inhibition of these channels leads to membrane 
potential depolarization, increased intracellular calcium and vasoconstriction of MMA 
(Figure 1-2). In marked contrast, KATP inhibition did not alter cerebral artery diameter. 
Our data also indicate that PKA activity underlies basal KATP channel activity observed in 
the MMA.  
Previous studies have suggested that KATP channels can be activated through a 
signal transduction pathway involving increased adenylyl cyclase activity, enhanced 
levels of cAMP and activation of PKA (Hayabuchi et al., 2001, Sampson et al., 2004). 
KATP channels can be phosphorylated and activated by PKA (Quinn et al., 2004, Shi et 
al., 2007) and exogenous agonists of cAMP such as forskolin can elicit KATP currents in 
isolated smooth muscle myocytes (Wellman et al., 1998). Our results provide strong 
evidence of ongoing PKA regulation of KATP channels in isolated pressurized MMA. 
However, the question still remains as to why PKA is basally active in this tissue?  One 
possibility could be basal release of neuropeptides such as calcitonin gene related peptide 
(CGRP) and pituitary adenylate cyclase activating polypeptide (PACAP) from trigeminal 
nerves, which heavily innervate the MMA (Ploug et al., 2008, Ploug et al., 2012). 
Receptors of these neuropeptides are Gs-cAMP coupled leading to increased PKA 
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activity and are present in MMA (Edvinsson et al., 1987, Edvinsson, 2015b, a). 
Additionally, it is plausible that protein phosphatase 1 (PP1) and/or protein phosphatase 
2A (PP2A) that are responsible for dephosphorylation, may have lower activity in MMA 
smooth muscle myoctes (Quinn et al., 2004, Brignell et al., 2015). Similarly, we can 
speculate that the activity of phosphodiesterase 3 (PDE3) may be attenuated in the MMA 
smooth muscle myocytes. PDE3 is the dominant isoform in vascular smooth muscle 
responsible for metabolizing and inactivating cAMP and this process is independent of 
physiological pressure (Elvebak et al., 2010).  However, it is also possible that the 
apparent increase in basal KATP activity in MMA compared to cerebral arteries represents 
a higher relative membrane resistance in MMA smooth muscle independent of KATP 
channel activity (Zimmermann et al., 1997).  
In conclusion, our data suggests that KATP channels may be playing a fundamental 
role in tonic regulation of MMA diameter. The MMA has been implicated in the 
pathophysiology of migraine headache and several vasodilators have been suggested to 
induce migraine like symptoms including KATP channel openers (D'Arcy et al., 1985, 
Goldberg, 1988, Sterndorff and Johansen, 1988, Ploug et al., 2008, Ploug et al., 2012). 
Thus, it is conceivable that aberrant signaling in KATP channels may contribute to the 
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 Figure 1: Tonic KATP channel activity contributes to MMA diameter regulation via 
membrane potential depolarization and increased intracellular calcium. (A) 
Representative traces demonstrating the effect of 10 µM glibenclamide on MMA at 40 
mmHg and cerebellar arteries at 60 mmHg. Bar graph represents summary data of 
glibenclamide and PNU37883-induced constriction in MMA vs cerebellar artery. Passive 
diameter (maximally dilatation) was induced by Ca2+-free aCSF containing 100 µM 
diltiazem and 1 µM forskolin. P < 0.01 for glibenclamide and P < 0.001 for PNU37883 in 
MMA vs cerebellar artery (B) Representative traces of smooth muscle membrane 
potential measurements in isolated MMA at 40 mmHg in the absence and presence of 10 




potential measurements obtained in the presence of 10 µM glibenclamide in MMAs. 
(n=5) P < 0.01 before treatment vs MMA, using paired t-test. (C) Representative trace of 
increased fura-2 340/380 nm emission ratio caused by  10 µM glibenclamide. Bar graph 
represents summary data of 10 µM glibenclamide-induced fura-2 calcium change (n=5). 







Figure 2: Basal PKA activity underlies tonic KATP channel activity in MMA. (A) 
Representative trace of 1 µM KT5720-induced vasoconstriction in the presence or 
absence of glibenclamide (10 µM). Bar graph represents summary data of glibenclmaide-
induced vasoconstriction in the presence and absence of 1 µM KT5720 (n=4) P < 0.01 
unpaired t-test. (B) Bar graph representing summary data of 1 µM KT5720-induced 
constriction in MMA vs. cerebellar artery (n=4 each) P < 0.01 unpaired t-test. (C) 
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Summary of cromakalim concentration-response curves of MMA and cerebellar arteries. 
EC50 values were 100 nM and 300 nM for cromakalim-induced concentration-dependent 
vasodialtion in the absence and presence of 1 µM KT5720 in MMA (n = 4 each). EC50 
value was 1 µM for cromakalim-induced concentration-dependent vasodilation in 













4.8 Supplemental Methods 
Methods 
All experiments were conducted in accordance with the Guide for the Care and Use of 
Laboratory animals (eighth edition, 2011) and approved by the Institutional Animal Use 
and Care Committee of the University of Vermont. Sprague–Dawley rats (males, 300–
350 g; Charles River Laboratories, Saint Constant, QC, Canada) were euthanized by 
decapitation under deep pentobarbital anesthesia. The brain and calvaria were carefully 
dissected and placed in ice-cold artificial cerebral spinal fluid (aCSF) in millimolar: 125 
NaCl, 3 KCl, 18 NaHCO3, 1.25 NaH2PO4, 1 MgCl2, 2 CaCl2, and 5 glucose (pH 7.4). 
Dura mater was removed from the calvaria and MMA dissected using iris scissors. 
Similarly cerebellar artery was dissected from the brain using iris scissors.  
Ex vivo diameter measurements: MMAs were cannulated onto glass micropipettes 
mounted in a 5-mL myograph chamber perfused with aCSF at 37 °C. The vessel was 
equilibrated for 1 hr at an intravascular pressure of 10 mmHg using a pressure servo-
controller and a peristaltic pump as previously described 8. Throughout the experiment, 
changes in vessel diameter were measured by video edge detection (Living Systems 
Instrumentation, St Albans, VT) using WinDaq data acquisition software (Dataq 
Instruments; Akron, OH). After allowing the arteries to equilibrate for 1 hour, viability of 
the artery was determined by brief superfusion with 60 mM KCl in artificial 
cerebrospinal fluid (aCSF; isosmotic replacement of NaCl with KCl). Only those arteries 
that constricted to at least 50% of its initial diameter in the presence of 60 mM KCl were 
used in subsequent studies. After initial viability tests the vessels were subjected to an 
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increase in intravascular pressure to 40 mmHg and allowed to develop myogenic tone 
(pressure-induced constriction). Myogenic tone is expressed as a percent decrease of the 
fully dilated diameter of individual arteries at the same intravascular pressure. The values 
were obtained by using the following equation:% myogenic tone= (DP-DA)/DP, where 
DP is the passive diameter of the artery in Ca2+-free aCSF containing the vasodilators 
diltiazem (100 µM) and forskolin (1 µM) and DA is the active diameter of the artery in 
Ca2+-containing aCSF . Vasoconstriction induced by a drug treatment was calculated 
using the following equation % constriction =  [(DA−DC)/DA]×100, where DA is the 
active diameter of the artery in Ca2+-containing aCSF and DC is the active diameter of 
the artery in Ca2+-containing aCSF with the drug during vasoconstriction. Similarly % 
dilation were obtained using the following equation: % dilation = [(DV-DA)/(DP-
DA)]x100, where DV is the diameter with vasodilator treatment, DA is the active 
diameter of the artery in Ca2+-containing aCSF  and DP  is the passive diameter of the 
artery in Ca2+-free aCSF containing the vasodilators diltiazem (100 µM) and forskolin (1 
µM). For experiments done in the presence of VDCC channels blocker (diltiazem), 
pressure was kept at 10 mmHg. This was done in order avoid complication due to 
pressure-induced constriction caused by myogenic tone.  
Ratiometric calcium measurments: Freshly isolated MMA were cannulated on glass 
micropipettes mounted in a 5-ml myograph chamber as detailed above. Arteries were 
then loaded with 5 µM of the ratiometric Ca2+-sensitive dye fura-2 acetoxymethyl ester 
(fura-2 AM, Invitrogen, Carlsbad, CA) in aCSF solution containing pluronic acid (0.1%) 
at room temperature (~22°C) for 1 hour. Next, the myograph chamber was mounted on a 
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Nikon TE2000-S inverted fluorescence microscope coupled with IonOptix calcium, 
diameter and flow system in pressurized vessels (Milton, MA). To allow for equilibration 
and de-esterification of fura-2 AM. Isolated MMA arteries were pressurized to 40 mmHg 
and continuously superfused (37°C, 30 min). Fura-2 was excited simultaneously by two 
separate wavelengths (340 and 380 nm) and fluorescence emission was measured at 510 
nm, the background signal was subtracted and the ratio between the intensity levels were 
used to calculate the free calcium concentration using the following equation: [Ca2+] = Kd 
(R-Rmin)/(Rmax-R)×(Sf2/Sb2) 28. Rmax and Rmin are the ratio values (F340/F380) measured 
under conditions of saturating calcium levels and in the absence of calcium respectively. 
Sb2 and Sf2 are proportional to the fluorescence excited by the denominator wavelength 
(380 nm) under the saturated calcium condition (Sb2) and in the absence of calcium (Sf2). 
Sb2 and Sf2 values were calculated in the presence of ionomycin with Ca2+ - free and 
saturated Ca2+ condition. The Kd value used is 282 nM as estimated previously by Knot et 
al., for fura-2 calcium binding 29. 
Membrane potential measurements: Arteries were cannulated as described above and 
pressurized to 40 mmHg (MMA) and 60 mmHg (cerebellar artery). Smooth muscle 
membrane potential was measured by insertion of a sharp glass microelectrode with 
resistance (~200 -MΩ) containing 0.5 M KCl into the vessel wall. The criteria for 
successful impalement are 1) an abrupt negative potential deflection upon entry, 2) a 
stable membrane potential for ≥30 s, and 3) an abrupt positive potential deflection upon 
removal 29. Measurements were made with an electrometer (World Precision 
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Instruments) and recorded via computer with Axotape and Dataq software. All recordings 
were done in the presence of 300 nM nimodipine. 
Statistics: Data are expressed as mean ± SEM and analyzed by Student’s paired and un-
paired t test. Statistical significance was considered at p<0.05. 
Chemicals: PNU37883, KT5720 and H89 were purchased from Tocris Bioscience 
(USA). Glibenclamide and rest of the chemicals were ordered from Sigma-Aldrich (St. 
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4.10 Supplemental Figures 
 
 
Supplemental Figure 1 (S 1): (A) Representative traces of smooth muscle membrane 
potential measurements in cerebellar artery at 60 mmHg in the absence and presence of 
10 µM glibenclamide. Bar graph represents summary of smooth muscle membrane 
potential measurements obtained in the presence of 10 µM glibenclamide in cerebellar 
arteries. (n=5)  (B) Representative trace of membrane potential in the absence and 
presence of vehicle (DMSO) used to solubilizing KATP channel inhibitor glibenclamide 
and PKA inhibitor H89 (1 µM). Bar graph represents summary data for effect of DMSO 
before and after treatment (n=4). (C) Representative trace of 10 µM glibenclamide 
induced membrane potential depolarization in the absence and presence of PKA inhibitor 
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H89. Bar graph represents summary data of 10 µM glibenclamide-induced depolarization 





Supplemental Figure 2 (S 2): (A-B) Representative trace of 10 µM glibenclamide-
induced diameter change at 10 mmHg in the absence (A) and presence (B) of the L-
VDCC blocker diltiazem (100 µM). (C) Bar graph representing summary data of 
glibenclamide-induced diameter change of rat MMA in the presence and absence of 









CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
 
The dura mater is heavily innervated by sensory nerves and acts not only as a 
protective barrier for the brain but also plays a key role in migraine headache (Asghar et 
al., 2010, Asghar et al., 2011, Amin et al., 2012, Chmielewski et al., 2013, Schueler et al., 
2013, Amin et al., 2014). The MMA is the main arterial branch supplying blood to the 
dura mater and vasodilation of this vascular bed has been hypothesized to play a critical 
role in migraine headache genesis (Asghar et al., 2011, Amin et al., 2012).  Furthermore, 
several researchers have hypothesized that the neuropeptide PACAP may be a key player 
in the generation of migraine headache; however, the reported effects of PACAP on 
MMA have been ambiguous (Schytz et al., 2009, Schytz et al., 2010a, Schytz et al., 
2010b, Baun et al., 2011, Baun et al., 2012). The research focus of my dissertation was to 
decipher the role of PACAP in the regulation of MMA diameter. During the course of 
this study, we also discovered that basal KATP channel activity contributes to the 
regulation of MMA diameter.   
In chapter two, we evaluated the effect of PACAP and VIP on MMA and cerebral 
arteries. Our findings demonstrated that PACAP is a potent vasodilator of the MMA, 
inducing vasodilation in MMA at picomolar concentrations as opposed to nanomolar 
concentrations in cerebral arteries. We further established that the PAC1-R-Hop splice 
variant of the PAC1 receptor is present in the MMA (Syed et al., 2012). However, 
although we detected PACAP receptors PAC1-R-Hop and VPAC2 transcripts in the 
MMA whole artery lysate, we did not determine the cellular location of these receptors 
and this remains to be resolved. PACAP receptors have been reported to be present on 
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vascular smooth muscle cells of MMA but have also been demonstrated to be present on 
dural mast cells encasing the MMA. Baun et al. have reported that activation of the PAC1 
receptor on dural mast cells induces degranulation invoking an inflammatory response by 
releasing histamine and cytokines such as TNF-α (Baun et al., 2012). It is possible that 
these inflammatory mediators along with PACAP act on vascular smooth muscle to 
induce a prolonged dilation of MMA.  One possible approach to examine this would be to 
use laser capture micro-dissection to specifically isolate MMA smooth muscle cells. 
RNA extraction and polymer chain reaction (PCR) could then confirm the presence of 
PAC1 receptors in MMA myocytes. 
Clinical studies have demonstrated that PACAP-induced dilation of MMA but not 
of the cerebral arteries is thought to be responsible for the onset of migraine headache 
(Asghar et al., 2010, Asghar et al., 2011, Amin et al., 2012, Amin et al., 2014). The 
mechanism by which PACAP is inducing dilation in the MMA and cerebral artery is not 
known. Therefore, in appendix one we explored the mechanism that PACAP employs in 
order to induce dilation in the MMA. We discovered that in the presence of KATP channel 
inhibitors PACAP-induced vasodilation of the MMA was abolished. This data suggested 
that PACAP works via KATP channels to induce vasodilation in the MMA (AU et al., 
2016). Further, BK channel inhibition and eNOS inhibition did not affect the PACAP-
induced vasodilation of MMA, suggesting that PACAP is working exclusively via KATP 
channels in the MMA vascular smooth muscle cells. In contrast, in chapter 3 we found 
that PACAP engaged both KATP and BK channels to induce vasodilation in cerebral 
arteries. The spatial and temporal regulation of KATP channels by PKA is not clear and 
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requires further investigation. However, A-kinase anchoring protein (AKAP) has been 
postulated to play a crucial role in specific PKA interactions providing higher fidelity and 
compartmentalization in cellular signaling (Marx et al., 2000, Nystoriak et al., 2014). 
Thus, PACAP receptors may be compartmentalized with KATP channels to form a 
complex in MMA smooth muscle cells. On the other hand, in cerebral artery myocytes, 
PACAP receptors may compartmentalize with both KATP and BK channels.  
Another future direction of this project would be the investigation of the 
interactions between PACAP, AKAP and PKA. Here, the first step would be to decipher 
the identity of the AKAP associated with PACAP receptors and PKA using co-
immunoprecipitation experiments. This technique utilizes antibodies that specifically 
bind to the protein of interest, in this case PACAP receptors, to precipitate the protein 
along with any proteins that exist with the receptor in a complex. This can then be 
followed by mass spectrometry to identify the proteins associating with the PACAP 
receptors, including AKAPs.  Further, super resolution microscopy would enable better 
visualization of the co-localization of the protein in question with PACAP receptors. 
Identification of the AKAP involved with PACAP signaling in vascular smooth muscle 
could potentially provide additional down-stream therapeutic targets for migraine 
headache.  
5.1 Regulation of membrane potential and vascular diameter by KATP channels 
 
Membrane potential is defined as the electrical potential difference due to 
separation of charges across the cell membrane. For an artery pressurized at physiological 
pressure, resting membrane potential is approximately -40 mV (Knot and Nelson, 1998). 
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Two major factors contribute to the membrane potential of the cell: 1) the concentration 
of the ions inside and outside the cell and 2) the permeability of these ions through the 
lipid bilayer of the cell. In order to calculate the membrane potential for a given condition 
we can utilize the Goldman Hodgkin-Katz (GHK) equation: 
𝐄𝐦 =  𝐑𝐓𝐅 𝐥𝐧(𝐏𝐊 𝐊! 𝐨𝐮𝐭 + 𝐏𝐍𝐚 𝐍𝐚! 𝐨𝐮𝐭 + 𝐏𝐂𝐥 𝐂𝐥! 𝐢𝐧𝐏𝐊 𝐊! 𝐢𝐧 + 𝐏𝐍𝐚 𝐍𝐚! 𝐢𝐧 + 𝐏𝐂𝐥 𝐂𝐥! 𝐨𝐮𝐭 ) 
Where Em = membrane potential, P = permeability of the specific ion, R = ideal gas 
constant T= temperature and F= Faraday’s constant. 
 As evident from the GHK equation, the membrane potential is regulated by 
different ionic species and therefore ion channels and plasma membrane pumps play a 
crucial role in the regulation of membrane potential. In vascular smooth muscle, a tight 
relationship exists between membrane potential and vasodilation i.e., a small change in 
membrane potential (~1 mV) will induce a significant change in the diameter of the 
artery (~7.5 µm) by increasing or decreasing of calcium entry via L-voltage gated 
calcium channels (L-VDCC) (Nelson and Quayle, 1995, Knot and Nelson, 1998).    
Potassium channels play a key role in regulation of vascular diameter by 
regulating membrane potential (Brayden et al., 1991, Brayden and Nelson, 1992, Nelson 
and Quayle, 1995, Brayden, 2002). In chapter four, we present evidence that KATP 
channels are involved in regulating MMA membrane potential and diameter. In contrast, 
pial arteries do not demonstrate tonic KATP channel activity. Our data not only suggest 
that KATP channels are tonically regulating MMA diameter but the reason for their tonic 
activation is due to basal activity of PKA. There are several possibilities to account for 
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basal PKA activity including but not limited to basal release of neuropeptides such as 
PACAP or CGRP from the trigeminal sensory nerve innervating the MMA. 
Alternatively, protein phosphatase 2B (PP2B) and or phosphodiestarase 3 (PDE3) 
activity may be low in the MMA smooth muscle cells (Quinn et al., 2004, Shi et al., 
2007, Elvebak et al., 2010). Therefore, the dephosphorylation of KATP channel or 
metabolism of cAMP maybe lower compared to cerebral artery smooth muscle. Future 
experiments for this project will aim to determine the source of PKA activation. 
Additionally, depolarization induced by KATP channel inhibition may further activate BK 
channels, which are functionally present in the MMA smooth muscle, thus the mV 
change that we have observed may be an effect of multiple channels being regulated 
rather than just the KATP channels alone. Furthermore, we cannot state unequivocally that 
the increased sensitivity to KATP channel inhibition represents a specific increase in KATP 
channel activity. For example, Zimmerman et al., have demonstrated that in diabetic rat 
cerebral arteries, KATP channel agonist sensitivity is diminished due to decrease in tonic 
nitric oxide (NO) release (Zimmermann et al., 1997). One possible future direction for 
this project could be to test the effect of KATP channel agonist (cromakalim) in the 
presence of NO inhibitors. The prediction would be that if basal NO activity is increasing 
KATP channel sensitivity in MMA, then in the presence of NO inhibitor, cromakalim EC50 
value would shift from 100 nM to 1 µM, similar to that of cerebral arteries. If this is 
indeed the case, the next step would be to explore how NO is regulating KATP channel 
sensitivity in the MMA myocytes. Further, it is possible that factors other than enhanced 
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basal KATP channel activity are causing the apparent increase in sensitivity to KATP 
channel inhibitors in this tissue. 
Another possible future direction for this project would be to examine KATP 
channel activity in isolated MMA smooth muscle cells. Using the whole cell patch clamp 
configuration, we can record KATP channel currents from isolated smooth muscle 
myocytes (Wellman et al., 1998, Hayabuchi et al., 2001). This would enable us to 
decipher if channel activity is higher in MMA myocytes compared to pial artery 
myocytes. Furthermore, this would also enable us to determine KATP channel density in 
MMA myocytes. Additionally, using the whole cell patch clamp configuration we can 
also test PKA and NO regulation of KATP channels in MMA myocytes (Wellman et al., 
1998, Hayabuchi et al., 2001). Inhibition of PKA using PKA inhibitor KT5720 should 
result in inhibition of KATP channel currents, confirming tonic KATP channel regulation by 
basal PKA activity. Furthermore, we can test effect of NO on KATP channel activity and 
sensitivity.  
Information gained from this research will not only help in providing a better 
understanding of the role of KATP channels in MMA diameter regulation but also help in 
identifying potential therapeutic targets for migraine headache. 
5.2 Unpublished observations 
 
 Like PACAP, CGRP is endogenously expressed throughout the body and has 
pleiotropic effects (1992). Interestingly both PACAP and CGRP co-localize in several 
types of nerve fibers including sensory neurons (Edvinsson et al., 2001). CGRP binds to 
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Gs-coupled calcitonin receptor like receptor (CRLR).  Accessory CRLR subunits, 
receptor activity modifying proteins (RAMPs), modulate the specificity and cell surface 
expression of the receptor. CGRP receptors have been shown to be present in vascular 
smooth muscle (Edvinsson et al., 1987)and in the endothelium (Brain and Grant, 2004). 
CGRP has been proposed to induce dilation via several different mechanisms. In 
mesenteric and coronary smooth muscle, CGRP has been shown to induce dilation via 
direct activation of KATP channels (Nelson et al., 1990, Wellman et al., 1998). In contrast, 
in vascular endothelium CGRP has been reported to work by activating endothelium 
nitric oxide synthase (eNOS) via PKA resulting in the production of nitric oxide, which 
in turn activates BK channels via cGMP and protein kinase G pathway in mice cerebral 
arteries (Brain and Grant, 2004). Our preliminary data indicate that KATP channels are not 
involved in CGRP-induced dilation in the MMA nor is CGRP working via activation of 
the NOS pathway in the vascular endothelium (appendix 2, Figure 1-2). CGRP receptors 
activate the cAMP-PKA signaling cascade (Brain and Grant, 2004). Therefore, it is 
possible that activation of PKA by CGRP mediated signaling results in activation of 
several vasodilatory pathways including activation of KATP, BK, and voltage gated 
potassium (Kv) channels and the sarcoplasmic/endoplasmic reticulum calcium ATPase 
(SERCA) pump (Perez and Toro, 1994, Lin et al., 2000, Hayabuchi et al., 2001, Brignell 
et al., 2015). A possible future direction for this project would be to test if CGRP-induced 
dilation is abolished in the presence of a combination of BK, KATP channel and SERCA 
pump inhibitors in endothelium denuded MMA. Our preliminary data demonstrate 
(Figure 4, appendix 2) that CGRP-induced vasodilation is inhibited in the presence of 
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high K+; suggesting that CGRP-induced vasodilation works via activation of K+ channels 
inducing membrane potential hyperpolarization.   
These preliminary findings are novel and potentially important, as both 
neuropeptides PACAP and CGRP have been implicated in migraine headache and 
reported to potently dilate MMA.  Even though these peptides have been reported to 
work via cAMP-PKA pathway our preliminary data demonstrates that they seem to be 
evoking two distinct mechanisms to induce MMA vasodilation. The logical question that 
comes to mind is: are CGRP and PACAP working in synergy to induce vasodilation in 
MMA? Elas et al., have demonstrated that in porcine ophthalmic artery low concentration 
of CGRP and PACAP together result in significantly increased vasorelaxation compared 
to individual effects of the peptides (Elsas and White, 1997). Additionally, our 
preliminary data suggest that PACAP and CGRP are working via two separate 
mechanisms in the MMA. Thus, the spatial regulation of PKA by the CGRP and PACAP 
receptors seems to be different in the MMA. Hence targeting both vasodilatory 
mechanisms of both peptides may lead to development of better therapeutic strategies. 
5.3 Clinical relevance 
 
PACAP and CGRP are being heavily investigated in the field of migraine 
headache (Kaiser and Russo, 2013, Tajti et al., 2014).  CGRP antagonists have been 
tested in clinical trails with disappointing results due to liver toxicity as a side effect (Ho 
et al., 2014). Currently, there is push to develop antagonists for PACAP receptors and 
more specifically PAC1 receptor antagonists (Schytz et al., 2009, Schytz et al., 2010a, 
Schytz et al., 2010b). Consistent with this line of investigation, previous studies have 
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shown that activation of KATP channels in the meningeal vessels may result in mild to 
moderate headache (Ploug et al., 2008, Ploug et al., 2012). Indeed, several clinical studies 
have reported side effects of KATP channel agonist as mild to severe headache (Goldberg, 
1988, Sterndorff and Johansen, 1988). Thus, this research may shed some light on the 
mechanism by which the MMA is being regulated by CGRP, PACAP and KATP channels. 
 
5.4 Conclusion 
 In conclusion, the MMA is a unique blood vessel. Vasodilation of this blood 
vessel by PACAP and CGRP has been suggested to induce migraine headache. PACAP 
antagonists and more specifically PAC1 receptor antagonists may be a potential 
therapeutic target for migraine headache. Furthermore, targeting both PACAP and CGRP 
together may result in an effective therapeutic strategy for alleviating the symptoms of 
migraine headache. Additionally, KATP channels in the MMA are responsible for in part 
setting the membrane potential and regulating MMA diameter. It is conceivable that 
aberrant signaling of KATP channels or the release of neuropeptides from the sensory 
neurons innervating the MMA smooth muscle can result in excessive prolong 
vasodilation and migraine headache. Our research has revealed a number of unique 
characteristics of the MMA. Our hope is that these findings will lead to better 
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1.1 Abstract  
 
 The homeostatic control of cranial and cerebral blood flow is essential for normal 
brain function.  Brain surface (cerebral) and meningeal (cranial) arteries/arterioles are 
densely innervated by sensory and autonomic fibers containing a variety of vasoactive 
peptides including pituitary adenylate cyclase activating polypeptide (PACAP, Adcyap1) 
which has been shown to exert potent vasodilatory effects in a variety of vascular beds.  
Recent studies have demonstrated that PACAP potency, activation of PACAP receptor 
subtypes and signaling to potassium channels to mediate vasodilatory responses are 
different between cerebral and cranial arteries, such as the cerebellar artery and the 
middle meningeal artery (MMA).  PACAP demonstrates exquisite picomolar potency at 
the PACAP-selective PAC1 receptor (Adcyap1r1) to activate ATP-sensitive potassium 
(KATP) channels of the MMA causing vasodilation. Although PACAP frequently 
colocalizes with the vasodilatory calcitonin gene related peptide (CGRP) in the fiber 
networks innervating the MMA, PACAP potency is nearly 3-orders of magnitude greater 
than that of CGRP.  CGRP is equipotent in the MMA and cerebral arteries.  In contrast, 
PACAP is a less potent vasodilator of cerebral arteries compared to the MMA, with 
nanomolar concentrations required to activate VPAC receptors leading to KATP and 
calcium-dependent potassium (BK) channel activation and cerebellar artery dilation.  
Further, PACAP’s effects on the brain are multidimensional. PACAP signaling also 
exerts direct neurotrophic and neuroprotective effects in the central nervous system 
against degenerative processes or physiological insults.  Thus, PACAP regulation of 
cerebral blood flow helps sustains brain metabolic demands, maintains neural 
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physiological functions— including learning and memory, and protects neurons from 
neurodegeneration in disease and trauma.  Coherent with CGRP vascular responses and 
functions, the vasodilatory effects of PACAP in the MMA also implicate a role in genesis 
of migraine disorders. 
Keywords: PACAP, PAC1 receptor, middle meningeal artery (MMA), cerebral arteries, 
cranial vessels, ATP-sensitive potassium channels (KATP), large conductance calcium 

















 Many regulatory peptides, including vasopressin, endothelin, calcitonin gene 
related peptide (CGRP), angiotensin peptides, natriuretic peptides, substance P, 
cholecystokinin, neuropeptide Y (NPY) and the vasoactive intestinal peptide 
(VIP)/pituitary adenylate cyclase activating polypeptide (PACAP) family of related 
peptides, have central roles in maintaining systemic and cerebrovascular homeostasis 
(Edvinsson et al., 2001, Goadsby, 2013). Of these peptides, PACAP has been identified 
in sensory and autonomic neuronal fibers along diverse arterial beds in numerous species 
(Mulder et al., 1994, Mulder et al., 1995, Sherwood et al., 2000, Baeres and Moller, 2004, 
Goadsby, 2013). Direct PACAP G protein-coupled PAC1 and VPAC receptor signaling 
within vascular smooth muscle cells has been shown to unvaryingly induce vasodilation 
with high potency and efficacy (Wilson and Warren, 1993, Anzai et al., 1995, Sherwood 
et al., 2000, Baun et al., 2011, Syed et al., 2012, Koide et al., 2014).  Among peripheral 
organs, PACAP fibers have been found to innervate vascular beds of the skin, eye, 
salivary glands, respiratory airways, cardiac tissues, gastrointestinal tract, mesentery, 
pancreas, kidney, testis, corpus cavernosum, ovary and placenta (Lerner et al., 1991, 
Uddman et al., 1991, Warren et al., 1992, Uddman et al., 1993, Wilson and Warren, 
1993, Graf et al., 1995, Hedlund et al., 1995, Steenstrup et al., 1996, Yao et al., 1996, 
Bruch et al., 1997, Elsas and White, 1997, Bruch et al., 1998, Dorner et al., 1998, 
Vuckovic et al., 2009, Banki et al., 2014a, Danyadi et al., 2014).  From this wide 
distribution, it is clear that PACAP plays an important role in maintaining vascular 
function throughout a broad spectrum of physiological systems. 
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 In addition, there is an increasing appreciation for the roles of PACAP in the 
regulation of cerebral hemodynamics.  Due to the high metabolic demands coupled with 
limited energy storage within the CNS, the blood supply to the brain must be continuous 
and operate within a narrow range to maintain structural and functional integrity of the 
brain (Brayden and Nelson, 1992, Nelson and Quayle, 1995, Li et al., 2014).  In this 
regard, the brain is like no other organ and highly susceptible to irreversible damage even 
upon transient ischemic events. Hence, a series of complex regulatory mechanisms 
preserve cerebrovascular homeostasis. Upon systemic vascular challenges, the brain, 
through neural and humoral control, can redirect and redistribute blood flow from the 
peripheral circulatory system to cerebral circulation. Complementary to these changes in 
blood flow dynamics, the cerebrovasculature also has autoregulatory mechanisms that 
can respond to the perturbations in arterial pressure that typically occur in the course of 
normal physiological activities. In addition, cerebral blood flow is differentially 
modulated by sensory/autonomic innervation, and astrocytic signaling along the length of 
the cerebral artery (Dunn and Nelson, 2014, Filosa et al., 2015). Pial, or brain surface 
arteries are densely innervated by sensory and autonomic sympathetic and 
parasympathetic fibers containing diverse regulatory transmitters and peptides for 
vasodilation (i.e., acetylcholine, CGRP, VIP, PACAP) and vasoconstriction 
(norepinehphrine, NPY) activities (Uddman et al., 1993, Edvinsson et al., 2001, Dunn 
and Nelson, 2014).  However, as vessels pass through the Virchow-Robin space and enter 
the brain parenchyma, extrinsic perivascular nerves disappear and intracerebral arterioles 
come under the regulatory control of astrocytic endfeet (Dunn and Nelson, 2014, Filosa 
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et al., 2015). Hence, cerebral arterial tone is regulated in part by sensory and autonomic 
peptides.  The homeostatic balance of cerebral blood flow is delicate but critical for 
normal brain function, and altered cerebrovascular activities from dysregulation, disease 
or trauma have been shown not only to precipitate stroke but contribute in other 
pathologies including neurodegenerative disorders, behavioral abnormalities and 
migraine (Asghar et al., 2011, Longden et al., 2014). The following sections highlight 
PACAP signaling mechanisms drawing data from our work in the middle meningeal and 
cerebellar arteries to provide insights into their potential roles in the regulation of 
cerebral and cranial blood flow (Syed et al., 2012, Koide et al., 2014).  
1.21 PACAP and PACAP receptors in cerebral and cranial vessels 
 
  The PACAP precursor molecule is endoproteolytically processed to PACAP27 or 
PACAP38 bioactive peptides, which share significant homology with VIP (Seidah et al., 
1994, Seidah and Chretien, 1999, Sherwood et al., 2000, Vaudry et al., 2009).  
Accordingly, PACAP and VIP share receptor subtypes.  PACAP peptides bind 
selectively at PAC1 receptors, but both VIP and PACAP bind with near equal affinity at 
VPAC1 and VPAC2 receptors.  PAC1 and VPAC receptors have been identified in 
cerebral and cranial arteries by immunocytochemistry, ligand binding studies, transcript 
analyses and physiological assays (Edvinsson et al., 2001, Baeres and Moller, 2004, Baun 
et al., 2011, Chan et al., 2011, Erdling et al., 2013).  Further, PACAP infusions have been 
shown to facilitate cerebral artery vasodilation in cranial window (Tong et al., 1993) and 
isolated vessel preparations (Anzai et al., 1995).  However, PACAP signaling 
mechanisms underlying vasodilation can differ among cerebral and cranial vascular beds 
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(see below). There are several sources that can supply PACAP to both cerebral and 
cranial vessels.  One is the trigeminal ganglion in which subpopulations of sensory 
neurons express a variety of vasoregulatory peptides including PACAP, VIP or CGRP 
(Uddman et al., 1993, Edvinsson et al., 2001).  As in dorsal root ganglion (DRG), 
PACAP is expressed in approximately 10% of the trigeminal neurons and frequently 
colocalized with CGRP for synergistic functions. The other potential sources of PACAP 
include the parasympathetic sphenopalatine and otic ganglia in the head; but the relative 
abundance of PACAP neurons in these ganglia has been highly variable ranging from 5 - 
6% to nearly all neurons in the population (Mulder et al., 1994, Mulder et al., 1995, 
Baeres and Moller, 2004). The reasons underlying the discrepancy are unclear but may 
reflect immunocytochemical vs in situ hybridization methods and detection of low 
PACAP-expressing neurons.  Retrograde tracing studies have suggested that the majority 
of the PACAP fibers in cerebral arteries are derived from peripheral trigeminal sensory 
axons (Baeres and Moller, 2004).  Our immunocytochemical studies demonstrating 
prevalent dual PACAP and CGRP colocalization in neuronal fibers along the middle 
meningeal artery are consistent with that interpretation (Figure 1), but many fibers also 
demonstrate PACAP-immunoreactivity alone suggesting that some may also be of 
postganglionic parasympathetic origins. 
 Both PAC1 and VPAC receptors have been described in cerebral and cranial 
vessels based on ligand binding, transcript analyses and pharmacological assessments.  
The relative abundance of each receptor subtypes in cerebral and cranial arteries has not 
been well characterized but these blood vessels undoubtedly express multiple PACAP 
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receptor classes and all are likely to have physiological roles (Tong et al., 1993, Uddman 
et al., 1993, Edvinsson et al., 2001, Baun et al., 2011, Syed et al., 2012, Koide et al., 
2014). PACAP peptides bind to all three receptors with high affinity and hence are 
relevant ligands regardless of receptor subtype expression. The vasodilatory effects of 
PACAP appear to be direct on arterial smooth muscle and largely endothelium-
independent (Huang et al., 1993, Wilson and Warren, 1993, Chan et al., 2011). 
1.22 PACAP mediates middle meningeal artery (MMA) vasodilation via PAC1 
receptor activation of KATP channels 
 
 Unlike many previous studies, we used an ex-vivo pressurized arteriograph 
system to examine the vasodilatory effects of PACAP on the MMA to obviate 
pharmacological approaches to pre-constrict the arteries. Myogenic tone (pressure 
induced constriction) is an intrinsic property of resistance arteries and largely dependent 
on the intraluminal pressure on the arterial walls.  Hence, ex-vivo pressurized 
arteriography utilizes this intrinsic property of the resistance arteries to mimic 
physiological conditions.  For these studies, the MMA was dissected from adult male rats 
and cannulated onto glass micropipettes as described previously (Syed et al., 2012). The 
artery was bathed continuously with artificial cerebral spinal fluid (aCSF) at 37 °C and 
the intraluminal pressure increased to 40 mmHg to allow development of myogenic tone. 
Upon artery constriction and stabilization, the peptides and drugs were added to the 
bathing solution to assess changes in vessel diameter, and at the end of the treatments, the 
maximum passive diameter of the artery was assessed in Ca2+-free aCSF containing 
vasodilator diltiazem (100 µM) and forskolin (1 µM). 
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 Using this approach, we found that PACAP38 potently dilated the MMA in a 
concentration dependent manner with an EC50 of 1 pM; VIP by contrast, was 
approximately 1000 - fold less potent and induced dilation in MMA with EC50 of 1.4 nM 
(Syed et al., 2012), which suggested that the PACAP effects were mediated by the 
PACAP selective PAC1 receptor.  MMA pretreatments with a PAC1/VPAC2 receptor 
antagonist PACAP6-38 (100 nM) completely abolished the vasodilation induced by 3 pM 
PACAP38.  However, 100 nM PACAP6-38 attenuated the vasodilatory effects of 3 nM 
PACAP38 by 50%, which may have reflected pharmacological mass action effects or 
potential roles for VPAC1 receptor signaling in the MMA.  Even though VPAC1 
receptors have been described in cerebral arteries (Baun et al., 2011), semi quantitative 
PCR analyses of rat MMA cDNA only detected prominent PAC1 and VPAC2 receptor 
transcript expression. These PCR results were consistent with the peptide potency studies 
in our pressurized vessel preparations, but whether MMA also demonstrates very low 
levels of VPAC1 receptor remains to be evaluated. Further, more detailed diagnostic 
restriction digest analyses of the PAC1 amplicon revealed that the MMA PAC1 receptor 
was predominantly the PAC1Hop1 receptor variant (Syed et al., 2012). This observation 
is notable and suggests that the MMA PAC1 receptor signaling is capable of engaging 
multiple intracellular second messenger cascades to elicit vascular responses. 
 Potassium channels play a crucial role in arterial tone via regulation of vascular 
smooth muscle membrane potential. Potassium channel activation causes vascular 
smooth muscle membrane hyperpolarization, leading to decreased L-type voltage-gated 
calcium channel (VDCC) open probability and a reduction of intracellular calcium to 
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facilitate smooth muscle relaxation and vasodilation. (Figure 4, modified from Koide et 
al., 2014) (Koide et al., 2014). From many studies, the PKA-dependent phosphorylation 
and activation of several potassium channels, including ATP-sensitive potassium (KATP) 
channels (Wellman et al., 1998), large conductance calcium-activated potassium (BK) 
channels (Standen and Quayle, 1998) and voltage gated potassium (KV) channels 
(Brignell et al., 2015) can participate in the cerebral vasodilatory process. Accordingly, 
the ability for PAC1Hop1 receptors to engage the adenylyl cyclase/cAMP/PKA pathway 
for potassium channel phosphorylation and activation represents a principal mechanism 
to stimulate MMA dilation. 
 Among the different potassium channels, our studies have shown that PACAP and 
PAC1 receptor activation of KATP channels is sufficient to induce MMA vasodilation 
(Figure 2 A-C, F). For these studies, the isolated MMA segments were again pressurized 
to 40 mmHg and allowed to develop myogenic tone, and 3 nM PACAP produced a 56.2 
± 7.6% increase in dilation.  However, in the presence of the KATP channel inhibitor 
glibenclamide (10 µM) or a vascular selective KATP channel inhibitor PNU37883 (10 
µM) (Wellman et al., 1999), the PACAP effects were completely abolished.  By contrast, 
MMA treatment with a BK channel inhibitor, paxilline (1 µM), failed to attenuate the 
PACAP vasodilatory responses (Figure 2 D, F). Furthermore, pretreatment with the 
competitive nitric oxide synthase inhibitor nitro-L-arginine (L-NNA, 100 µM) had no 
effect on PACAP-mediated MMA vasodilation (Figure 2 E, F).  Together, these results 
suggest that PACAP/PAC1 receptor-mediated activation of cAMP/PKA and KATP 
channels can regulate MMA tone exclusively without engaging BK channel functionor 
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nitric oxide (NO) production. The spatial and temporal regulation of KATP channels by 
PKA requires further investigation but A-kinase anchoring proteins (AKAPs) have been 
postulated to play crucial roles in conferring the specific PKA interactions needed for 
channel regulatory fidelity (Kapiloff and Chandrasekhar, 2011). 
1.23 PACAP and CGRP demonstrate differential potencies in stimulating MMA 
vasodilation 
 
 Described earlier, PACAP and CGRP are frequently colocalized in the fiber 
networks around the cerebral arteries including the MMA (Figure 1).  CGRP also has 
vasodilatory functions via G protein-coupled calcitonin receptor-like receptors (CALCR). 
We have begun to examine whether there are differences between PACAP and CGRP in 
their vasodilatory activities with respect to potency, efficacy or signaling mechanisms.  
Using the same ex-vivo pressurized MMA vessel preparation, concentration-dependence 
studies demonstrated that the EC50 for CGRP-induced MMA dilation was 1 nM, which 
was comparable to the potency of VIP, but again 1000-fold lower than that for PACAP-
mediated vasodilation (EC50 1 pM). These results appeared to agree with previously 
published data in which PAC1 receptor-stimulated increase in cAMP production was 
500-fold more potent than that of CGRP (Lerner et al., 1991). The efficacy of PACAP 
and CGRP in MMA vasodilation appeared comparable; the mechanisms underlying the 





1.24 PACAP mediates cerebellar artery vasodilation via different receptors and 
channels 
 
 Unlike the responses in MMA, PACAP and VIP dilated cerebellar arteries with 
equal potency.  Using the same ex-vivo procedures to perfuse the cannulated cerebellar 
arterial segments, PACAP38 and VIP induced vasodilation with an EC50 of 11 nM and 6 
nM, respectively (Syed et al., 2012, Koide et al., 2014).  All three VIP/PACAP receptor 
subtypes have been identified in cerebral arteries but distinct from the MMA in which 
PAC1 receptor signaling was implicated, the near equal potency of VIP and PACAP in 
eliciting cerebellar arterial dilation indicated that the responses were largely mediated by 
VPAC receptors.  
 In cerebellar arteries, PACAP-mediated stimulation of the cAMP/PKA pathway 
not only activated KATP channels but also BK channels to increase spontaneous transient 
outward currents (STOCs) for vasodilation (Jaggar et al., 1998, Wellman et al., 2001, 
Wellman and Nelson, 2003, Brayden et al., 2013, Koide et al., 2014).  The BK channels, 
like KATP channels, can be activated by direct PKA phosphorylation (Wellman et al., 
2001, Wellman and Nelson, 2003), but characteristically, BK channels are regulated by 
local increases in intracellular calcium (Ca2+ sparks).  PACAP signaling and stimulation 
of PKA can potentially activate ryanodine receptors (RyRs) on the sarcoplasmic 
reticulum (SR) for intracellular calcium release, resulting in a localized transient increase 
in cytosolic calcium up to 10 µM, termed a calcium spark (Brayden and Nelson, 1992, 
Jaggar et al., 1998, Wellman et al., 2001).  These calcium spark events in turn can lead to 
localized BK channel activation on the plasma membrane (Figure 4).  Additionally, PKA 
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can also phosphorylate phospholamban (PLB), a pentameric protein that regulates the 
sarcoplasmic reticulum calcium-ATPase (SERCA) pump, critical for the management of 
intracellular calcium. PLB in the unphosphorylated state inhibits SERCA activity; 
PACAP activation of PKA and downstream phosphorylation of PLB relieves that 
inhibition to increase SERCA activity and sarcoplasmic reticulum calcium load, resulting 
in increased calcium spark frequency and BK channel activity (Brayden and Nelson, 
1992, Jaggar et al., 1998, Wellman et al., 2001).  Unlike the MMA studies, the addition 
of the KATP channel blocker glibenclamide or the BK channel blocker paxilline only 
attenuated and did not abolish the PACAP-induced vasodilation in cerebellar arteries 
(Figure 3 B-C, E, modified from Koide et al., 2014).  However, the concurrent addition 
of glibenclamide and paxilline fully eliminated the PACAP vasodilatory responses 
(Figure 3 D, E, modified from Koide et al 2014) (Koide et al., 2014). These findings 
suggest that similar to coronary and pulmonary arteries (Bruch et al., 1997, Bruch et al., 
1998), PACAP regulates cerebral artery tone via both KATP and BK channels, but in 
contradistinction, PACAP only regulates KATP channels for MMA vasodilation.  
1.25 Alternate mechanism of PACAP-induced vasodilation 
 
 There is evidence suggesting PACAP-induced dilation may also be endothelium-
dependent in certain species. For example in newborn pigs, studies using an in vivo 
closed cranial window system suggested that the PACAP-induced vasodilation may be 
mediated partially through cyclooxygenase (COX). Intravenous injections of COX1 
inhibitor SC-560 (1 mg/kg) appeared to significantly decrease PACAP-induced 
vasodilation whereas treatments with a COX2 specific inhibitor NS-398 (1 mg/kg) had no 
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apparent effects (Lenti et al., 2007).  The mechanisms by which PACAP signaling can 
engage COX1 are unclear. 
1.26 Functional significance of PACAP regulation and pathophysiology 
 
 Cerebrovascular homeostasis to maintain blood flow is essential for normal brain 
activities. Pial arteries present the greatest resistance to cerebral blood flow and cerebral 
artery relaxation after neurotransmitter/neuropeptide release from sensory and autonomic 
nerve terminals can contribute significantly to vasodilation in downstream branches 
(Iadecola, 2004). The dynamic homeostatic changes in cerebral blood flow is essential to 
meet metabolic demands, and failures to meet those demands from cerebrovascular 
dysfunction have been associated with impairments in learning and memory which may 
lead to vascular dementia, and increased risks for Alzheimer’s and related 
neurodegenerative diseases (Claassen, 2015). PACAP receptor activation can engage 
neurotrophic signaling pathways for neuroprotection against injuries, but the abilities for 
PACAP to regulate vasodilation and cerebral blood flow may offer means to mitigate 
ischemic damage (Elsas and White, 1997, Banki et al., 2014b, Danyadi et al., 2014). 
 Recently, there has been interest in PACAP signaling in the MMA and migraine.  
Migraine is a complex and often debilitating neurological disorder characterized by 
intense unilateral pulsating headache, frequently accompanied with aura, photophobia, 
phonophobia, nausea and related symptoms (Asghar et al., 2011, Edvinsson, 2015). The 
causes of migraine are not understood and are likely to be multifactorial.  One 
mechanism that has been debated for decades implicates MMA vasodilation from 
trigeminal sensory and/or sphenopalatine parasympathetic fiber innervation and 
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signaling.  A different and more recent concept suggests that migraine results from 
cortical spreading depression (Ayata, 2010, Cui et al., 2014). But regardless whether 
MMA vasodilation plays a causal or contributory role in the pathophysiology of 
migraine, there is good evidence that vasodilatory peptides participate in migraine 
development. As described in previous work, CGRP is localized to sensory fibers 
innervating the MMA, facilitates MMA vasodilation, and can induce migraine-like 
headaches similar to spontaneous migraine attacks. Magnetic resonance angiography 
imaging correlated MMA vasodilation with migraine onset upon exogenous CGRP 
infusions and notably, CGRP receptor antagonists can ameliorate migraine headaches 
(Asghar et al., 2010, Asghar et al., 2011).  However, clinical trials examining the efficacy 
of the CGRP receptor antagonists were halted because of liver toxicity (Bigal and Walter, 
2014). More recently, plasma PACAP levels have been reported to be elevated in patients 
with migraine (Tuka et al., 2013). Further, PACAP is associated with post-traumatic 
stress disorder (PTSD), which is highly comorbid with migraine, suggesting an 
intersection of PACAP mechanisms and neural pathways (Bukovics et al., 2014). As 
described above, PACAP is frequently colocalized with CGRP in sensory fibers 
innervation the MMA and similar to CGRP, exogenous PACAP administration can 
initiate migraine ipsilateral to the infusion site coincident with MMA vasodilation (Amin 
et al., 2012, Amin et al., 2014). Specific small molecule PACAP receptor antagonists 
have yet to be identified but blocking MMA PACAP signaling, either alone or in 
combination with CGRP receptor antagonists, may offer means for migraine therapeutics.  
From these examples, a better understanding of PACAP and VIP neurocircuits and 
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signaling mechanisms regulating cerebral arterial tone may be clinically relevant for a 
number of neurophysiological disorders and states. 
1.3 Conclusion 
 
 The regulation of cerebrovascular resistance is essential to meet brain metabolic 
demands and function.  PACAP has potent vasodilatory activities in a variety of vascular 
systems including the cerebral and cranial arteries.  The PACAP fibers innervating the 
cerebral arteries are sensory or autonomic in origin, and interestingly, PACAP potency, 
the PACAP receptor subtypes and the downstream signaling mechanisms mediating the 
vasodilatory effects appear to vary for cranial blood vessels.  PACAP signaling via the 
PAC1 and VPAC receptors in the MMA activates exclusively KATP channels for 
vasodilation; the PACAP effects on cerebellar arteries appear to be primarily mediated by 
VPAC receptor regulation of KATP and BK channels.  Thus the roles of PACAP in the 
brain are multidimensional.  In addition to its direct trophic and protective activities on 
neurons, the roles of PACAP in regulating blood vessel diameter may be important in 
maintaining learning and memory, and mitigating brain damage from ischemic events. 
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Figure 1: PACAP and CGRP immunoreactivities are colocalized in fibers 
innervating the MMA. Rat MMA was dissected from the dura, perfusion fixed in 4% 
paraformaldehyde and immunocytochemically dually processed for PACAP (1:10, Jen 
Hannibal, Bisperg Hospital, Copenhagen Denmark) and CGRP (1-17) (1:1500, Ian 
Dickerson), University of Rochester) for visualization with Cy3 (PACAP, red, left panel) 
and AlexaFluor 488 (CGRP, green, middle panel), respectively. The fluorescent signals 
were merged (yellow, left panel) to illustrate high levels of colocalization; the 
distribution patterns suggested that the fibers were sensory in origin from the trigeminal 




Figure 2: PACAP-induces MMA vasodilation through KATP channel activation.  
Segments of the MMA were cannulated and pressurized for superfusion experiments as 
described previously (Syed et al.).  MMA perfusions with 3 nM PACAP-induced 
produced maximal vasodilation (A; n = 8).  The addition of KATP channel inhibitor 
glibenclamide (B; GLIB, 10 µM, N = 4) or the vascular selective KATP channel inhibitor 
PNU37883 (C; PNU, 10 µM, n=4) blocked the PACAP vasodilatory effects.  By contrast, 
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treatments with the BK channel inhibitor paxilline (D; PAX, 1 µM, n = 4) or the nitric 
oxide synthase inhibitor L-NNA (E; 100 µM, n = 4) had no effects. The data are 
summarized in (F) represent as mean ± SE. ***, significantly different from PACAP 
alone (CTRL, control) at p < 0.001. One-way ANOVA followed by post hoc 















Figure 3: PACAP-induced dilation in isolated cerebellar artery is mediated via both 
KATP and BK channels. (A) Representative trace of 3 nM PACAP-induced vasodilation 
of cerebellar artery. (B-C) Representative traces of 3 nM PACAP-induced vasodilation in 
the presence of KATP channel inhibitor, glibenclamide (Glib) (10 µM) (B) and BK 
channel inhibitor, paxilline (Pax) (1 µM) (C). The vasodilation was significantly 
attenuated but not abolished. (D) Representative trace of 3 nM PACAP-induced 
vasodilation in the presence of 10 µM glibenclamide and 1 µM paxilline combined. The 
combined treatment with glibenclamide and paxilline abolished 3 nM PACAP-induced 
vasodilation in cerebellar artery. (E) Summary data of PACAP-induced vasodilation of 
cerebellar artery in the absence and presence of glibenclamide and paxilline (n = 4-7). 
Data are expressed as mean ± SE. * P<0.05, **P<0.01 vs PACAP-induced dilation in the 
absence of K+ channel blockers (control). Reproduced and modified with permission 




Figure 4: Schematic of PACAP mechanisms in vascular smooth muscle vasodilation. 
(A) PACAP binding to PAC1 G protein-coupled receptors stimulates cAMP/PKA 
pathways, resulting in KATP channel phosphorylation and activation.  The ensuing 
hyperpolarization closes voltage-dependent calcium channels (VDCC) and reduces 
intracellular calcium to facilitate smooth muscle relaxation and vasodilation.  This is the 
principal PACAP vasodilatory mechanism in MMA.  (B) In cerebellar arteries, PACAP-
mediated cAMP/PKA signaling by binding to VPAC1/2-R, can also activate calcium-
sensitive potassium (BK) channels by direct channel phosphorylation (not shown), 
activation of ryanodine receptors (RyR) or disinhibition of phospholamban (PLB) on the 
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sarcoplasmic reticulum ATPase pump (SERCA). The latter mechanisms increase 
sarcoplasm reticulum calcium release and spark generation to activate BK channels.  The 
BK mechanisms are synergistic with those via KATP for cerebellar artery vasodilation.  
Reproduced and modified with permission from the Journal of Molecular Neuroscience 
























APPENDIX 2: UNPUBLISHED OBSERVATION 
 
TITLE: Mechanism of CGRP-induced vasodilation of the middle meningeal artery 
2.1 Introduction  
Migraine is the most common incapacitating neurological disorder, characterized 
by an intense pulsating headache (Goadsby et al., 2002). It accounts for 1 % of total 
disability and has an economic burden of $20 billion in missed work and loss of 
productivity per year in the United States (Shapiro, 2007). Currently, treatments for 
migraine headache are relatively ineffective and fraught with adverse effects. 
Approximately 50 % of migraine suffers take over-the-counter medications, or nothing at 
all.  The cellular mechanisms contributing to migraine headache are poorly understood, 
but a leading hypothesis is that prolonged dilation of cranial arteries, and specifically the 
middle meningeal artery (MMA), is involved in the sensation of headache pain.  Recent 
clinical studies have shown that administration of pituitary adenylate cyclase activating 
polypeptide (PACAP) or calcitonin gene related peptide (CGRP) induce migraine-like 
headaches that coincide with unilateral MMA vasodilation.  Furthermore, following 
treatment with sumatriptan, a 5-HT-1B/D receptor agonist, PACAP and CGRP-induced 
headaches are attenuated corresponding to constriction of the MMA (Schytz, 2010, 
Asghar et al., 2011, Amin et al., 2012).   
Our lab has recently demonstrated that PACAP is a potent vasodilator of rat 
MMA exclusively via activation of ATP-sensitive potassium (KATP) channels (AU et al., 
2016). The goal of this study was to compare and contrast the mechanism of 
neuropeptides PACAP and CGRP-induced vasodilation implicated in migraine headache.  
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Our novel data indicate that although PACAP and CGRP have both traditionally been 
linked to increased adenylyl cyclase activity, the downstream mechanisms leading to 
MMA vasodilation are distinct for these neuropeptides. Considering the evidence 
indicating that PACAP- and CGRP-induced MMA dilation contribute to migraine 
headache (Asghar et al., 2010, Asghar et al., 2011, Amin et al., 2012, Amin et al., 2014), 
targeting both of these pathways is likely to provide added benefit to migraine patients.  
2.2 Methods 
 
MMAs were cannulated onto glass micropipettes mounted in a 5-mL myograph 
chamber perfused with aCSF at 37 °C, (aCSF in millimolar:125 NaCl, 3 KCl, 18 
NaHCO3, 1.25 NaH2PO4, 1 MgCl2, 2 CaCl2, and 5 glucose, aerated with 5 % CO2, 20 % 
O2, 75 %N2, pH 7.35–7.40). Intravascular pressure was adjusted using a pressure servo-
controller and a peristaltic pump as previously described (Ishiguro et al., 2002, Nystoriak 
et al., 2011). Throughout the experiment, changes in vessel diameter were measured by 
video edge detection (Living Systems Instrumentation, St Albans, VT) using WinDaq 
data acquisition software (Dataq Instruments; Akron, OH). After initially allowing the 
arteries to equilibrate for 1 hour, viability and integrity of the artery was determined by 
brief superfusion with 60 mM KCl in artificial cerebrospinal fluid (aCSF; isosmotic 
replacement of NaCl with KCl). Only arteries that constricted by 50% or more 
(calculated from % decrease of resting diameter) were used in subsequent studies. 
Pressure-induced constriction is expressed as a percent decrease of the fully dilated 
diameter of individual arteries at the same intravascular pressure. These values will be 
obtained by using the following equation: % constriction =  [(DP−DA)/DP]×100, where 
182 
 
DP is the passive diameter of the artery in Ca2+-free aCSF containing the vasodilators 
diltiazem (100 µM) and forskolin (1 µM), and DA is the active diameter of the artery in 
Ca2+-containing aCSF. Dilation in response to PACAP38 and CGRP are expressed as a 
percent reduction in the level of arterial constriction. The values are obtained using the 
following equation: % dilation [(DV−DA)/(DP−DA)]×100, where DV is arterial diameter 
in the presence of vasodilator, DA is the active diameter of the artery prior to addition of 
vasodilator, and DP is the passive diameter of the artery. 
Ratiometric calcium measurements: Freshly isolated MMA were cannulated on glass 
micropipettes mounted in a 5-ml myograph chamber as described above. After 
cannulation, arteries were loaded with 5 mM of the ratiometric Ca2+-sensitive dye fura-2 
acetoxymethyl ester (fura-2 AM, Invitrogen, Carlsbad, CA) in HEPES-buffered saline 
solution containing pluronic acid (0.1%) at room temperature (~22°C) for 1 hour. Next, 
the myograph chamber was mounted on a Nikon TE2000-S inverted fluorescence 
microscope. To allow for equilibration and de-esterification of fura-2 AM, isolated MMA 
sections were pressurized to 10 mmHg, were continuously superfused with aCSF (37°C, 
for 30 min). Fura-2 was excited by two separate wavelengths (340 nm and 380 nm) and 
fluorescence emission at 510 nm was measured; the background signal was subtracted 
and the ratio between the intensity levels was used to calculate the free calcium 
concentration using the following equation: [Ca2+] = Kd (R-Rmin)/(Rmax-R)×(Sf2/Sb2). 
Rmax and Rmin are the ratio values measured under conditions of saturating calcium levels 
and in the absence of calcium respectively. Sb2 and Sf2 are proportional to the 
fluorescence excited by the denominator wavelength (380 nm) under the saturated 
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calcium condition (Sb2) and in the absence of calcium (Sf2). These values were measured 
from a separate set of ionomycin treated arteries under Ca2+-free and Ca2+-saturated 
conditions. The Kd value used is 282 nM for fura-2 calcium binding. 
2.3 Results 
CGRP-induced dilation of MMA is independent of KATP channels  
CGRP has been shown to induce dilation in vascular smooth muscle through KATP 
channels (Quayle et al., 1994a, Wellman et al., 1998) via the cAMP-PKA pathway 
(Wellman et al., 1998). However, in the presence of the KATP channel inhibitors, 
glibenclamide (10 µM) or PNU37883 (10 µM), CGRP-induced dilation of MMA was 
unaffected (Figure 1 B-D). These results indicate that KATP channels are not involved in 
CGRP mediated dilation of MMA. 
BK and KV channels are not involved in CGRP induced dilation 
  PKA has been shown to phosphorylate and activate BK channels and voltage 
gated potassium (KV) channels in vascular smooth muscle (Nelson et al., 1995, Ko et al., 
2010). Interestingly, CGRP-induced MMA dilation was not altered by the BK channel 
inhibitor (Bol et al., 2012) paxilline (1 µM) or the KV channel inhibitor 4-aminopyridine 
(4-AP, 5 mM) (Figure 2 B-C). 
Nitric oxide, cyclooxygenase and SK/IK channels inhibition do not alter CGRP-
induced dilation of MMA 
  CGRP has been proposed to induce vasodilation via endothelial-dependent nitric 
oxide synthase in mice pial arteries (Rosenblum et al., 1993). However, our data indicate 
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that inhibition of eNOS with L-NNA (100 µM) did not reduce CGRP-induced dilation of 
MMA (Figure 2 D). Additionally, we also tested other endothelium-dependent 
vasodilatory pathways including cyclooxygenase (COX). In the presence of COX 
inhibitor indomethacin (10 µM), CGRP-induced vasodilation remained unaffected. 
Furthermore, activation of calcium activated intermediate conductance potassium (IK) 
channel and calcium activated small conductance potassium channel (SK) in the vascular 
endothelium induce vasodilation via membrane potential hyperpolarization (Hannah et 
al., 2011). However, the IK inhibitor  TRAM34 (1µM) and the SK inhibitor apamin  (300 
nM) also did not alter CGRP-induced vasodilation of MMA (Figure 2 E-G).  
CGRP induces a decrease in arterial wall calcium 
To examine whether a decrease in arterial wall calcium underlies CGRP-induced 
MMA dilation, ratiometric calcium measurements were made using Fura-2 in isolated 
pressurized MMA segments.  As illustrated in Figure 3, CGRP-induced dilation was 
accompanied by a decrease in calcium that was comparable to the decrease in calcium 
caused by the KATP channel opener cromakalim. These data demonstrate that CGRP-
induced dilation in MMA results from a decrease in intracellular calcium.  
CGRP-induced dilation is abolished by increased extracellular K+ 
CGRP has been shown to induce membrane potential hyperpolarization via 
potassium channel activation (Quayle et al., 1994a) resulting in decreased open 
probability of VDCC and decreased intracellular Ca2+ in vascular smooth muscle. To 
examine whether shifting the K+ equilibrium potential (EK) to a more depolarized 
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membrane potential influenced CGRP-induced dilations, arteries were pre-constricted 
with either 30 mM KCl or 10 nM U46619 (thromboxane analog). In the presence of 30 
mM potassium, EK is calculated to be -38mV with no net K+ movement into or out of the 
cells. CGRP-induced dilation was markedly reduced in the presence of high extracellular 
potassium compared to 10 nM U46619, suggesting that potassium channel activation and 
smooth muscle membrane potential hyperpolarization play a role in CGRP-induced 
dilation of MMA (Figure 9A-B).  
2.4 Significance and future directions 
 
Previous studies have demonstrated that CGRP-induced relaxation of vascular 
smooth muscle is primarily through the activation of KATP channels (Nelson et al., 1990). 
However, data presented in the following study argues that CGRP-induced dilation of 
MMA is working via an alternative mechanisms. Conversely, PACAP is working through 
the activation of KATP channels in the MMA, while in cerebral artery PACAP utilizes 
both KATP and BK channels (Syed et al., 2012, Koide et al., 2014). Both PACAP and 
CGRP have been shown to co-localize and released from the trigeminal sensory nerve 
during migraine. Furthermore, PACAP and CGRP induced relaxation in vascular smooth 
muscle has been traditionally linked to increased adenylyl cyclase activity and PKA 
activation (Quayle et al., 1994b, Vaudry et al., 2009). However, we have not tested if 
CGRP is working via PKA pathway in the MMA to induce vasodilation. Additionally, 
we have not ruled out the involvement of vascular endothelium in CGRP-induced dilation 
of the MMA. In the future, deciphering the involvement of PKA and endothelium will 
help focus on the mechanism of CGRP-induced dilation of MMA. If CGRP does indeed 
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signal via PKA activation to cause dilation in the MMA, then it becomes important to 
examine the spatial regulation of PKA by CGRP and PACAP. A-Kinase anchoring 
proteins (AKAPs) have been suggested to play a crucial role in temporal and spatial 
regulation of PKA (Marx et al., 2000, Nystoriak et al., 2014).  Therefore, additional 
experiments are required to decipher specific AKAP association with CGRP or PACAP 
receptors so we can better understand downstream signaling cascades. 
Our preliminary data demonstrate that CGRP is working via membrane potential 
hyperpolarization. This hyperpolarization is due to the activation of potassium channels 
as in the presence of high potassium (30 mM) CGRP-induced vasodilation is completely 
abolished (Figure 4). Furthermore, our Fura 2 data show that CGRP-induced vasodilation 
is calcium dependent as there is a decrease in intracellular smooth muscle calcium 
following CGRP treatment (Figure 3).   
CGRP can utilize multiple pathways to induce vasodilation in the MMA. For 
example, PKA has been demonstrated to regulate not only KATP channels but also BK 
and Kv channels in the vascular smooth muscle (Brignell et al., Perez and Toro, 1994, 
Marx et al., 2000, Hayabuchi et al., 2001, Shi et al., 2007). PKA can also regulate 
sarcoplasm/endoplasmic reticulum calcium ATPase (SERCA) pump in vascular smooth 
muscle cells, resulting in increased SERCA activity and decreased cytosolic calcium 
(Wellman and Nelson, 2003). Therefore in future, we must examine CGRP-induced 
dilation in the presence of a combination of pharmacological inhibitors of the KATP, BK 
and Kv channels in conjunction with SERCA pump inhibitors.  
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 By understanding the distinct mechanisms involved in MMA dilation caused by 
CGRP and PACAP, it may be possible to develop new combination therapies for 






Figure 1: CGRP-induced dilation is not attenuated in the presence of glibenclamide 
and PNU37883. A-C) Representative traces of 1 nM CGRP-induced dilation in the 
presence or absence of KATP channel inhibitor glibenclamide (10 µM) and PNU37883 (10 
µM). D) Summary data for CGRP-induced dilation in presence or absence of 
glibenclamide and PNU37883, n = 5 each. Unpaired student t-test. Glibenclamide vs 
control and PNU37883 vs control. 
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Figure 2: CGRP-induced dilation is independent of BK, Kv, eNOS, COX, IK and 
SK pathways. A-G) Representative traces of 1 nM CGRP-indiced dilation in the absence 
(A) and presence of BK channel inhibitor paxilline (1 µM, n = 4)) (B), Kv channel 
inhibitor 4-AP (5 mM, n = 1)) (C), eNOS inhibitor L-NNA (100 µM, n = 1) (D), 
cyclooxygenase inhibitor indomethacin (10 µM, n=3) (E), IK/SK channel inhibitors 
Apamin and TRAM34 (300 nM and 1 µM respectively, n = 4) (F), combination of L-
NNA (100 µM), Indomethacin (10 µM), Apamin (300 nM) and TRAM34 (1 µM) (G). 



















































Figure 3: CGRP induces a decrease in intracellular calcium paralleling MMA 
dilation. A-B) Representative traces of CGRP and cromakalim-induced dilation. C-D) 
Representative traces of ratiometric calcium decrease following treatment of 1 nM CGRP 
(C) and 1µM cromakalim (D). Summary data of ratiometric calcium measurements in 





Figure 4: CGRP-induced dilation is significantly attenuated in the presence of high 
extracellular potassium. A) Representative trace of 1 nM CGRP response in the 
presence of 30 mM KCl. B) Representative trace of 1 nM CGRP response in the presence 
of 10 nM U46619 (n = 4). C) Summary data for CGRP-induced dilation in MMA in the 
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